Springe direkt zu Inhalt

Abstractbeiträge

  • D. Busse, L. Ehmann, P. Simon, D. Petroff, N. Hartung, R. Michelet, W. Huisinga, H. Wrigge,
    C. Kloft.
    Probability of target attainment by conventional pharmacokinetic/pharmacodynamic targets is
    overestimated in obese patients receiving linezolid and meropenem.
    30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Paris, France, 18-21 April 2020. Abstract book, 3022, (2020).

  • R. Michelet, J. Seeger, C. Kloft.
    A mechanism-based pharmacokinetic/pharmacodynamic model based on pharmacokinetic and
    static time-kill data alone can predict the in vitro bacterial regrowth of 3 fluoroquinolone-resistant Escherichia coli strains after dynamic exposure.
    30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Paris, France, 18-21 April 2020. Abstract book, 1243, (2020).

  • F. Weinelt, M. Stegemann, A. Theloe, F. Pfäfflin, L. Dübel, A. Uhrig, S. Achterberg,
    R. Lorenz, H.J. Epple, L. Ehmann, W. Huisinga, S. Hennig, C. Kloft.
    Utilising the full potential of model-based dosing tables: an interprofessional collaboration to develop and integrate meropenem dosing tables into clinical routine.
    30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Paris, France, 18-21 April 2020. Abstract book, 795, (2020).

  • L. Ilia, D. Busse, L. Ehmann, P. Simon, R. Michelet, C. Kloft.
    Identification and quantification of microdialysis variabililty using an integrated in vitro, ex vivo and in silico approach.
    30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID),
    Paris, France, 18-21 April 2020. Abstract book, 3795, (2020).

  • J. Seeger, R. Michelet, S. Guenther, C. Kloft.
    Beyond the minimal inhibitory concentration: Novel pharmacokinetic/pharmacodynamic metrics quantify the exposure-effect relationship of levofloxacin against fluoroquinolone resistant Escherichia coli based on in vitro infection models.
    30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID),
    Paris, France, 18-21 April 2020. Abstract book, 3065, (2020).

  • J. Schulz, R. Michelet, F. Kluwe, C. Kloft.
    Clinical feasibility of simultaneous microdialysis of voriconazole and its N-oxide metabolite at target site demonstrated by in vitro investigations.
    30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID),
    Paris, France, 18-21 April 2020. Abstract book, 848, (2020).

  • A. Démaris, A.M. Grišić, W. Huisinga, W. Reinisch, C. Kloft.
    Evaluation of dosing strategies of anti-TNFα monoclonal antibodies using pharmacokinetic modelling and simulation.
    15th Congress of European Crohn’s and Colitis Organisation (ECCO), Vienna, Austria,
    12-15 February 2020.
    https://doi.org/10.1093/ecco-jcc/jjz203.201

  • L. Klopp-Schulze, A. Mueller-Schoell, M. Joerger, P. Neven, S.L.W. Koolen,
    R.H.J. Mathijssen, S. Schmidt, C. Kloft.
    At the interface of physiologically-based and nonlinear mixed-effects modelling: Enhancing the quantitative understanding of the complex pharmacokinetics and -genetics of tamoxifen and its major metabolites.
    10th American Conference on Pharmacometrics (ACoP), Florida, USA, 20-23 October 2019.
    Abstract book, 252, (2019).

  • F. Kluwe, M. Maas, A. Hennige, B. Weber, C. Kloft.
    How predictive is short-term body-weight loss in the long term for decision making during clinical drug development?
    10th American Conference on Pharmacometrics (ACoP), Florida, USA, 20-23 October 2019.
    Abstract book, 226, (2019).

  • A. Mueller-Schoell, L. Klopp-Schulze, W. Huisinga, M. Joerger, P. Neven, S.L.W. Koolen,
    R.H.J. Mathijssen, S. Schmidt, C. Kloft.
    296P Patient-tailored tamoxifen dosing based on an increased quantitative understanding of its
    complex pharmacokinetics: A novel integrative modelling approach.
    Ann. Oncol. 30: Suppl_5, mdz241.004 (2019).
    https://doi.org/10.1093/annonc/mdz241.004

  • J. Grensemann, D. Busse, C. König, W. Jäger, D. Jarczak, S. Iwersen-Bergmann, C. Kloft, S. Kluge, V. Fuhrmann.
    Pharmacokinetics of meropenem in critically ill patients with and without acute-on-chronic liver failure undergoing continuous venovenous hemodialysis.                                          
    Intensive Care Med Exp 7 (Suppl 3): 55 (2019).
    https://icm-experimental.springeropen.com/track/pdf/10.1186/s40635-019-0265-y

  • F.W. Ojara, A. Henrich, N. Hartung, W. Huisinga, M. Joerger, C. Kloft.
    Leveraging parametric time-to-event analysis: suggested increase in risk of peripheral neuropathy with weekly over 3-weekly paclitaxel dosing in advanced NSCLC.
    Annual Meeting of the Central European Society of Anticancer Drug Research (CESAR), Oldenburg, Germany, 12-14 September 2019.
    Abstract book, 26, (2019).

  • A. Mueller-Schoell, L. Klopp-Schulze, R. Michelet, W. Huisinga, M. Joerger, C. Kloft.
    Assessing the impact of non-adherence on endoxifen target attainment in tamoxifen breast cancer therapy using a modelling & simulation framework.
    Annual Meeting of the Central European Society of Anticancer Drug Research (CESAR), Oldenburg, Germany, 12-14 September 2019.
    Abstract book, 23, (2019).

  • A. Alahdab, R. Michelet, M. Habes, A. Sievers, J. Kassler, J. Ziemann, C. Kloft, C.A. Ritter.
    Effect of CIP2A inhibitor bortezomib alone and in combination with erlotinib on cell growth of erlotinib resistant non-small cell lung cancer cells.
    Annual Meeting of the Central European Society of Anticancer Drug Research (CESAR), Oldenburg, Germany, 12-14 September 2019.
    Abstract book, 26, (2019).

  • L. Klopp-Schulze, M. Joerger, C. Kloft.
    Model-based precision dosing of tamoxifen therapy.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Heidelberg, Germany, 01-04 September 2019.
    https://www.dphg.de/fileadmin/downloads/DPhG-ConferenceBook_2019.pdf, 82, (2019).

  • J. Schulz, J.F. Joseph, C. Kloft.
    Bioanalytical method validation for the quantification of voriconazole in microdialysate: An assay for small sample volumes and low concentrations.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Heidelberg, Germany, 01-04 September 2019.
    https://www.dphg.de/fileadmin/downloads/DPhG-ConferenceBook_2019.pdf, 131, (2019).

  • D. Busse, P. Simon, L. Ehmann, D. Petroff, C. Dorn, W. Huisinga, R. Michelet, H. Wrigge,
    C.  Kloft.                                                                                                                   
    Differences in meropenem pharmacokinetics between obese and non-obese surgery patients are
    largely explained by body size and estimated creatinine clearance.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Heidelberg, Germany, 01-04 September 2019.
    https://www.dphg.de/fileadmin/downloads/DPhG-ConferenceBook_2019.pdf, 155, (2019).

  • J. Seeger, R. Michelet, S. Günther, C. Kloft.
    Determinants of growth-kill behaviour of fluoroquinolone resistant Escherichia coli under levofloxacin exposure in a dynamic in vitro infection model.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Heidelberg, Germany, 01-04 September 2019.
    https://www.dphg.de/fileadmin/downloads/DPhG-ConferenceBook_2019.pdf, 162, (2019).

  • A. Mueller-Schoell, S. Bielesch, L. Klopp-Schulze, R. Michelet, W. Huisinga, M. Joerger,
    C. Kloft.
    Computational treatment simulations to assess the risk for non-efficacy in tamoxifen treatment for breast cancer patients of different ethnicities.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Heidelberg, Germany, 01-04 September 2019.
    https://www.dphg.de/fileadmin/downloads/DPhG-ConferenceBook_2019.pdf, 163, (2019).

  • L. Ilia, R. Michelet, D. Busse, L. Ehmann, C. Kloft.
    Identification and quantification of microdialysis variability using a dynamic in vitro microdialysis system and nonlinear mixed-effects modelling.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Heidelberg, Germany, 01-04 September 2019.
    https://www.dphg.de/fileadmin/downloads/DPhG-ConferenceBook_2019.pdf, 159, (2019).

  • J. Seeger, R. Michelet, C. Kloft.
    What drives regrowth of fluoroquinolone resistant Escherichia coli under levofloxacin exposure in a dynamic in vitro infection model?
    American Society for Microbiology (ASM) Microbe, San Francisco, USA, 20-24 June 2019.
    [https://www.abstractsonline.com/pp8/#!/7859/presentation/16865], (2019).

  • A.M. Grišić, A. Khandelwal, M. Bertolino, W. Huisinga, C. Kloft*, P. Girard*.
    Semimechanistic clearance models of oncology monoclonal antibodies and impact of study design: cetuximab as a case study.
    28th Population Approach Group Europe (PAGE), Stockholm, Sweden, 11-14 June 2019.
    PAGE 28: 8994 [https://www.page-meeting.org/default.asp?abstract=8994], (2019).
    *Shared senior authorship

  • A. Lehmann, I. Geburek, A. These, X. Yang, S. Hessel-Pras, C. Kloft, C. Hethey.
    Toxicokinetic modelling of hepatotoxic pyrrolizidine alkaloids: a combined in silico, in vitro and in vivo apporoach.  
    28th Population Approach Group Europe (PAGE), Stockholm, Sweden, 11-14 June 2019.
    PAGE 28: 9154 [https://www.page-meeting.org/default.asp?abstract=9154], (2019).

  • D. Busse, P. Simon, D. Petroff, L. Ehmann, R. Michelet, C. Dorn, W. Huisinga, H. Wrigge, C. Kloft.
    Model-informed precision dosing for tamoxifen therapy in breast cancer patients: Comparison of different target attainment metrics.
    28th Population Approach Group Europe (PAGE), Stockholm, Sweden, 11-14 June 2019.
    PAGE 28: 8993 [https://www.page-meeting.org/default.asp?abstract=8993], (2019).

  • F.A. Weinelt, L. Ehmann, R. Michelet, W. Huisinga, J. Zander, M. Zoller, C. Kloft.
    A joint pharmacokinetic model for piperacillin/tazobactam including mechanistic renal clearance in critically ill patients.
    28th Population Approach Group Europe (PAGE), Stockholm, Sweden, 11-14 June 2019.
    PAGE 28: 9093 [https://www.page-meeting.org/default.asp?abstract=9093], (2019).

  • A. Mueller-Schoell, L. Klopp-Schulze, R. Michelet, W. Huisinga, C. Kloft.
    Model-informed precision dosing for tamoxifen therapy in breast cancer patients: Comparison of different target attainment metrics.
    28th Population Approach Group Europe (PAGE), Stockholm, Sweden, 11-14 June 2019.
    PAGE 28: 8900 [https://www.page-meeting.org/default.asp?abstract=8900], (2019).

  • R. Michelet, A.R. Brochado, A. Typas, S.G. Wicha, C. Kloft.
    A workflow for application of the general pharmacodynamic interaction model on
    high-throughput combinatorial data in order to identify, quantify and characterise drug combinations that can overcome multi-drug-resistance.
    28th Population Approach Group Europe (PAGE), Stockholm, Sweden, 11-14 June 2019.
    PAGE 28: 8866 [https://www.page-meeting.org/default.asp?abstract=8866], (2019).

  • L. Ilia, R. Michelet, D. Busse, P. Simon, C. Dorn, L. Ehmann, C. Kloft.
    Quantitative comparison of in vitro and in vivo variability of microdialysis experiments using nonlinear mixed-effects modelling on the example of linezolid.
    28th Population Approach Group Europe (PAGE), Stockholm, Sweden, 11-14 June 2019.
    PAGE 28: 9134 [https://www.page-meeting.org/default.asp?abstract=9134], (2019).

  • F.W. Ojara, A. Henrich, N. Hartung, W. Huisinga, M. Joerger, C. Kloft.
    Time-to-event analysis framework to evaluate the impact of paclitaxel exposure on peripheral
    neuropathy in patients with advanced non-small cell lung cancer receiving first-line chemotherapy.
    28th Population Approach Group Europe (PAGE), Stockholm, Sweden, 11-14 June 2019.
    PAGE 28: 9054 [https://www.page-meeting.org/default.asp?abstract=9054], (2019).

  • V. Stachanow, J. Melin, R. Michelet, O. Blankenstein, U. Neumann, W. Huisinga, R. Ross,
    M. Whitaker, C. Kloft.
    Does dried blood spot data enrich our understanding of hydrocortisone pharmacokinetics in
    paediatric patients with adrenal insufficiency?
    28th Population Approach Group Europe (PAGE), Stockholm, Sweden, 11-14 June 2019.
    PAGE 28: 9097 [https://www.page-meeting.org/default.asp?abstract=9097], (2019).

  • F. Kluwe, C. Kirbs, F. Drescher, P. Matzneller, W. Huisinga, M. Zeitlinger, C. Kloft.
    Model-based characterisation of nonlinear voriconazole pharmacokinetics following two different routes of administration.
    28th Population Approach Group Europe (PAGE), Stockholm, Sweden, 11-14 June 2019. PAGE 28: 9130 [https://www.page-meeting.org/default.asp?abstract=9130], (2019).

  • S. Stübler, C. Kloft,  W. Huisinga.
    Systems biology model of the mucosal immune system.
    28th Population Approach Group Europe (PAGE), Stockholm, Sweden, 11-14 June 2019.
    PAGE 28: 8861 [https://www.page-meeting.org/default.asp?abstract=8861], (2019).

  • U. Falkenhagen, C. Kloft,  W. Huisinga.
    Structural model selection: Is the chi-square distribution appropriate for likelihood ratio testing?
    28th Population Approach Group Europe (PAGE), Stockholm, Sweden, 11-14 June 2019.
    PAGE 28: 9090 [https://www.page-meeting.org/default.asp?abstract=9090], (2019).

  • C. Maier, N. Hartung, C. Kloft,  W. Huisinga.
    Quantifying the uncertainty: informative decision support in individualised chemotherapy.
    28th Population Approach Group Europe (PAGE), Stockholm, Sweden, 11-14 June 2019.
    PAGE 28: 8843 [https://www.page-meeting.org/default.asp?abstract=8843], (2019).

  • V. Stachanow, J. Melin, R. Michelet, O. Blankenstein, U. Neumann, W. Huisinga, R. Ross,
    M. Whitaker, C. Kloft.
    Semi-mechanistic modelling of hydrocortisone pharmacokinetics in paediatric patients with adrenal insufficiency.
    17th Congress of the European Society for Developmental Perinatal and Paediatric Pharmacology (ESDPPP), Basel, Switzerland, 28-30 May 2019.
    http://dx.doi.org/10.1136/archdischild-2019-esdppp.131 (2019).

  • A. Mueller-Schoell, R. Michelet, W. Huisinga, A. Künkele, C. Kloft.
    CAR-T cell therapy: Investigating clinical challenges using a modelling & simulation framework.
    17th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, 21-23 May 2019.
    Abstract book, 70-71, (2019).

  • A.M. Grišić#, M. Dorn-Rasmussen#, B. Ungar, J.F. Ilvemark, W. Huisinga, N. Bolstad,
    D.J. Warren, S. Ben-Horin, M.A. Ainsworth, J. Brynskov, C. Kloft*, C. Steenholdt*.
    Infliximab clearance is decreased during 2nd and 3rd trimesters of pregnancy in inflammatory bowel disease.
    Digestive Disease Week, San Diego, 18-21 May 2019.
    Gastroenterology 156: 18 (2019).
    #equal contribution
    *shared senior authorship
    doi: https://doi.org/10.1016/S0016-5085(19)36816-7

  • I.K. Minichmayr, S.G. Wicha, P. Matzneller, C. Kloft, M. Zeitlinger.
    Impact of single key components of intensified ceftaroline dosing to pharmacokinetic/pharmacodynamic target attainment.
    29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Amsterdam, The Netherlands, 13-16 April 2019.
    https://www.escmid.org/escmid_publications/escmid_elibrary/?q=Minichmayr&id=2173&L=0&x=9&y=24, (2019).

  • R. Michelet, A.R. Brochado, S.G. Wicha, A. Typas, C. Kloft.
    Quantitative characterisation of the interaction between colistin and macrolide drugs in clinical isolates of Gram-negative Enterobacteriaceae using the general pharmacodynamic interaction model.
    29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Amsterdam, The Netherlands, 13-16 April 2019.
    https://www.escmid.org/escmid_publications/escmid_elibrary/?q=Michelet&id=2173&L=0&x=20&y=22, (2019).

  • S. Franck, R. Michelet, F. Casilag, J.C. Sirard, S.G. Wicha, C. Kloft.
    Boosting the immune system to enhance amoxicillin activity: Insights provided by semi-mechanistic PK/PD modelling.
    29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Amsterdam, The Netherlands, 13-16 April 2019.
    https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=68652, (2019).

  • L. Ilia, R. Michelet, C. Kloft.
    Establishing a dynamic in vitro microdialysis system to identify sources of variability using nonlinear mixed-effects modelling.
    29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Amsterdam, The Netherlands, 13-16 April 2019.
    https://www.escmid.org/escmid_publications/escmid_elibrary/?q=Ilia&id=2173&L=0&x=0&y=0, (2019).

  • S. Franck, R. Michelet, F. Casilag, J.C. Sirard, S.G. Wicha, C. Kloft.
    Boosting the immune system to enhance amoxicillin activity: Insights provided by
    semi-mechanistic PK/PD modelling.
    Annual meeting of the International Society of Anti-Infective Pharmacology (ISAP) 2019, Rotterdam, The Netherlands, 12 April 2019.
    https://isap.org/index.php/annual-meeting/annual-meeting-2019, (2019).

  • J. Seeger, R. Michelet, C. Kloft.
    Exploiting the exposure-effect relationship of levofloxacin against fluoroquinolone restistant Escherichia coli isolates in a dynamic in vitro infection model.
    Annual meeting of the International Society of Anti-Infective Pharmacology (ISAP) 2019, Rotterdam, The Netherlands, 12 April 2019.
    https://isap.org/index.php/annual-meeting/annual-meeting-2019, (2019).

  • S. Hennig, C. Kloft.
    How many NMLE articles are published in higher impact factor clinical journals?
    20th Annual Population Approach Group of Australia and New Zealand (PAGANZ) meeting,
    Auckland, New Zealand, 06-09 February 2019.
    https://www.paganz.org/abstracts/how-many-nmle-articles-are-published-in-higher-impact-factor-clinical-journals/(2019).

  • F.W. Ojara, M. Joerger, W. Huisinga, C. Kloft.
    Therapeutic drug monitoring as a tool to reduce the occurrence of paclitaxel-associated peripheral neuropathy in patients with advanced NSCLC.
    3rd International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD), Amsterdam, Netherlands, 08-09 November 2018.

  • L. Ilia, D. Burau, S. Schröpf, H.-G. Münch, R. Michelet, H. Derendorf, C. Kloft.
    Dose optimisation of vancomycin in neonates and infants based on a microdialysis feasibility study.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Hamburg, Germany, 02-05 October 2018. https://www.dphg.de/fileadmin/downloads/DPhG2018_ConferenceBook_Final_27-09-2018.pdf, 141, (2018).

  • F.A. Weinelt, L.Ehmann, R. Marrek, W. Huisinga, J. Zander, M. Zoller, C. Kloft.
    Variability of piperacillin serum concentrations in intensive care patients.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Hamburg, Germany, 02-05 October 2018. https://www.dphg.de/fileadmin/downloads/DPhG2018_ConferenceBook_Final_27-09-2018.pdf, 141, (2018).

  • V. Stachanow, J. Melin, O. Blankenstein, U. Neumann, W. Huisinga, R.J. Ross, M. Whitaker, C. Kloft.
    Semi-mechanistic modelling of hydrocortisone pharmacokinetics in paediatric patients including dried blood spot data.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Hamburg, Germany, 02-05 October 2018. https://www.dphg.de/fileadmin/downloads/DPhG2018_ConferenceBook_Final_27-09-2018.pdf, 141, (2018).

  • F. Kluwe, M. Ansin, D. Burau, R. Schwameis, W. Huisinga, M. Zeitlinger, C. Kloft.
    Pharmacometrics-based optimisation of antiinfective therapy exploiting target-site pharmacokinetics assessed by microdialysis – opportunities and case study with cefuroxime.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Hamburg, Germany, 02-05 October 2018. https://www.dphg.de/fileadmin/downloads/DPhG2018_ConferenceBook_Final_27-09-2018.pdf, 145, (2018).

  • S. Franck, T. Fuhrmann-Selter, J.F. Joseph, R. Michelet, F. Casilag, J.C. Sirard, S.G. Wicha*, C. Kloft*.
    An in vivo-in silico approach to assess the pharmacokinetics of a novel concept combining amoxicillin with an immunomodulatory drug.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Hamburg, Germany, 02-05 October 2018. https://www.dphg.de/fileadmin/downloads/DPhG2018_ConferenceBook_Final_27-09-2018.pdf, 142, (2018).

  • J. Seeger, C. Kloft.
    Exploring pharmacokinetic/pharmacodynamic relationships of levofloxacin against resistant Escherichia coli in a dynamic in vitro infection model.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Hamburg, Germany, 02-05 October 2018. https://www.dphg.de/fileadmin/downloads/DPhG2018_ConferenceBook_Final_27-09-2018.pdf, 139, (2018).

  • S. Stübler, C. Kloft, W. Huisinga.
    Systems biology model of the mucosal immune system in the context of inflammatory bowel disease.
    International Conference on Systems Biology (ICSB), Lyon, France, 28 October-01 November 2018.
    Abstract book, 226 (2018).

  • S. Stübler, C. Kloft, W. Huisinga.
    Systems biology model of the mucosal immune system in the context of inflammatory bowel disease.
    11th Berlin Late Summer Meeting, Berlin, Germany, 25-27 October 2018.
    Abstract book, P112 (2018).

  • C. Maier, N. Hartung, C. Kloft, W. Huisinga.Individualising model-based predictions of neutropenia for decision support in oncology using sequential Bayesian data assimilation.
    Bayes 2018 Bayesian Biostatistics, Cambridge, UK, 20-22 June 2018.
    https://www.bayes-pharma.org/wp-content/uploads/2018/05/Corinna-Maier.pdf,
    https://www.bayes-pharma.org/?page_id=767.

  • F. Kluwe, M. Ansin, R. Schwameis, D. Burau, W. Huisinga, M. Zeitlinger, C. Kloft.
    Joint model for the characterisation of cefuroxime pharmacokinetics in synovial fluid, interstitial fluid of muscle tissue and plasma.
    27th Population Approach Group Europe (PAGE), Montreux, Switzerland, 29 May-01 June 2018.
    PAGE 27: 8668 [www.page-meeting.org/default.asp?abstract=8668], (2018).

  • A.M. Grisic, A. Eser, W. Huisinga, W. Reinisch, C. Kloft.
    Towards a comprehensive PK/PD model of infliximab in inflammatory bowel diseases, with support of prior knowledge.
    27th Population Approach Group Europe (PAGE), Montreux, Switzerland, 29 May-01 June 2018.
    PAGE 27: 8555 [www.page-meeting.org/default.asp?abstract=8555], (2018).

  • F.W. Ojara, A. Henrich, N. Hartung, M. Joerger, M. Roessler, N. Frances, W. Huisinga, C. Kloft.
    A time-to-event analysis of paclitaxel-related peripheral neuropathy in patients with advanced non-small cell lung cancer receiving first line chemotherapy.
    27th Population Approach Group Europe (PAGE), Montreux, Switzerland, 29 May-01 June 2018.
    PAGE 27: 8610 [www.page-meeting.org/default.asp?abstract=8610], (2018).

  • C. Maier, N. Hartung, C. Kloft, W. Huisinga.
    Improving model-based predictions of neutropenia using sequential data assimilation.
    27th Population Approach Group Europe (PAGE), Montreux, Switzerland, 29 May-01 June 2018.
    PAGE 27: 8432 [www.page-meeting.org/default.asp?abstract=8432], (2018).

  • S. Stübler, C. Kloft, W. Huisinga.
    Systems biology model of the mucosal immune system in the context of inflammatory bowel disease.
    27th Population Approach Group Europe (PAGE), Montreux, Switzerland, 29 May-01 June 2018.
    PAGE 27: 8742 [www.page-meeting.org/default.asp?abstract=8742], (2018).

  • S. Fuhrmann, C. Kloft, W. Huisinga.
    Cell-level based tumor cPBPK model to study mAb distribution within solid tumors and implications for efficacious treatment.
    27th Population Approach Group Europe (PAGE), Montreux, Switzerland, 29 May-01 June 2018.
    PAGE 27: 8657 [www.page-meeting.org/default.asp?abstract=8657], (2018).

  • J. Knöchel, C. Kloft, W. Huisinga.
    Focusing on essential dynamics of systems pharmacology models by exploiting an input-response characterisation.
    27th Population Approach Group Europe (PAGE), Montreux, Switzerland, 29 May-01 June 2018.
    PAGE 27: 8798 [www.page-meeting.org/default.asp?abstract=8798], (2018).

  • S. Franck, F. Casilag, J.C. Sirard, M. Rumbo, S.G. Wicha, C. Kloft.
    Towards developing unconventional antibiotic treatments – an in vitro approach to study the direct and indirect effects of immune modulators.
    28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, Spain, 21-24 April 2018.
    https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=63805, (2018).

  • F. Casilag, L. Matarazzo, D. Cayet, C. Carnoy, S. Franck, S.G. Wicha, C. Kloft, J.C. Sirard.
    Targetting innate immunity to improve antibiotic therapy in pneumococcal pneumonia.
    28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, Spain, 21-24 April 2018.
    https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=62331, (2018).

  • F.W. Ojara, A. Henrich, N. Hartung, M. Joerger, M. Roessler, J.v. Pawel, N. Frances,
    W. Huisinga, C. Kloft.
    Time-to-event analysis reveals a 50% reduction in incidence of peripheral neuropathy with PK/PD-guided dosing of paclitaxel in non-small cell lung cancer patients.
    Annual Meeting of the Central European Society of Anticancer Drug Research (CESAR), Berlin, Germany, 15-17 March 2018.
    Abstract book, 41 (2018).

  • L. Klopp-Schulze, M. Joerger, C. Kloft.
    One dose fits all or a more individualised tamoxifen dosing strategy?
    Annual Meeting of the Central European Society of Anticancer Drug Research (CESAR), Berlin, Germany, 15-17 March 2018.
    Abstract book, 35 (2018).

  • M. Schulz, L. Klopp-Schulze, S. Keilhack, S. Meyer, L. Botermann, C. Kloft.
    Adherence management of oral tamoxifen treatment: Who is involved?
    Annual Meeting of the Central European Society of Anticancer Drug Research (CESAR), Berlin, Germany, 15-17 March 2018.
    Abstract book, 18 (2018).

  • C. Maier, N. Hartung, C. Kloft, W. Huisinga.
    How weather forecasting methods can support individualised chemotherapy.
    Annual Meeting of the Central European Society of Anticancer Drug Research (CESAR), Berlin, Germany, 15-17 March 2018.
    Abstract book, 42 (2018).

  • S. Fuhrmann, C. Kloft, W. Huisinga.
    Antibody drug conjugates targeting solid tumors: Understanding the link between plasma trough concentration and their tumor distribution.
    Annual Meeting of the Central European Society of Anticancer Drug Research (CESAR), Berlin, Germany, 15-17 March 2018.
    Abstract book, 43 (2018).

  • L. Klopp-Schulze, M. Joerger, C. Kloft.
    How promising is model-informed precision dosing in tamoxifen therapy?
    46th ESCP Symposium on Clinical Pharmacy, Heidelberg, Germany, 09-11 October 2017.
    Abstract book, TDMP001 (2017).

  • M. Schulz, S. Keilhack, S. Meyer, L. Botermann, L. Klopp-Schulze, C. Kloft.
    Adherence to tamoxifen in breast cancer patients – Which role does the pharmacist play?
    46th ESCP Symposium on Clinical Pharmacy, Heidelberg, Germany, 09-11 October 2017.
    Abstract book, CP-PC045 (2017).

  • L. Ehmann, M. Zoller, I.K. Minichmayr, M.V. Schmitt, N. Hartung, W. Huisinga, J. Zander, C. Kloft.
    Development of a tool to identify intensive care patients at risk of meropenem therapy failure.
    46th ESCP Symposium on Clinical Pharmacy, Heidelberg, Germany, 09-11 October 2017. Abstract book, RD008 (2017).

  • A.M. Grisic, A. Eser, W. Huisinga, W. Reinisch, C. Kloft.
    Pharmacokinetic-pharmacodynamic, disease- and patient-related considerations for the optimisation of infliximab therapy in inflammatory bowel disease.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Saarbrücken, Germany, 27-29 September 2017.
    https://www.dphg.de/fileadmin/downloads/DPhG2017_ConferenceBook_final.pdf, 115, (2017).

  • F.I. Kluwe, C. Kirbs, F. Drescher, P. Matzneller, W. Huisinga, M. Zeitlinger, C. Kloft.
    Variability of voriconazole exposure after approved sequence dosing in humans.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Saarbrücken, Germany, 27-29 September 2017.
    https://www.dphg.de/fileadmin/downloads/DPhG2017_ConferenceBook_final.pdf, 114, (2017).

  • S. Franck, M. Si-Tahar, S.G. Wicha, C. Kloft.
    Evaluation of pharmacodynamic interactions: which criterion provides the right answer? A case study with colistin and streptomycin in Pseudomonas aeruginosa.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Saarbrücken, Germany, 27-29 September 2017.
    https://www.dphg.de/fileadmin/downloads/DPhG2017_ConferenceBook_final.pdf, 114, (2017).

  • L. Klopp-Schulze, M. Joerger, C. Kloft.
    Which tamoxifen dosing strategy might be most appropriate in breast cancer treatment?
    2nd International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD), Madrid, Spain, 13-14 September 2017.
    Abstract book, P_06 (2017).

  • S. Stübler, C. Kloft, W. Huisinga.
    Towards a systems biology model for inflammatory bowel disease.
    International Conference on Systems Biology of Human Disease (SBHD), Heidelberg, Germany, 05-07 July 2017.
    SBHD: 30 [http://www.sbhd-conference.org/2017/images/Alphabetical_list_poster_presenters-SBHD_2017.pdf], (2017).

  • F.W. Ojara, A. Henrich, N. Hartung, M. Joerger, M. Roessler, J. v. Pawel, W. Huisinga,
    C. Kloft.
    Examining the relationship between paclitaxel exposure and peripheral neuropathy in
    non-small cell lung cancer.
    26th Population Approach Group Europe (PAGE), Budapest, Hungary, 06-09 June 2017.
    PAGE 26: 7278 [www.page-meeting.org/default.asp?abstract=7278], (2017).

  • F.I. Kluwe, C. Kirbs, L. Ehmann, F. Drescher, P. Matzneller, W. Huisinga, M. Zeitlinger,
    C. Kloft.
    Population pharmacokinetics of unbound voriconazole following two different routes of administration during sequence therapy.
    26th Population Approach Group Europe (PAGE), Budapest, Hungary, 06-09 June 2017.
    PAGE 26: 7321 [www.page-meeting.org/default.asp?abstract=7321], (2017).

  • L. Ehmann, P.  Simon, D. Petroff, I.K. Minichmayr, D. Burau, M. Zeitlinger, C. Dorn,
    W. Huisinga, H. Wrigge, C. Kloft.
    Is a pooled population pharmacokinetic model predictive of plasma and microdialysate pharmacokinetics of linezolid in obese and non-obese patients?
    26th Population Approach Group Europe (PAGE), Budapest, Hungary, 06-09 June 2017.
    PAGE 26: 7322 [www.page-meeting.org/default.asp?abstract=7322], (2017).

  • A.M. Grisic, H. Edlund, A. Eser, W. Huisinga, W. Reinisch, C. Kloft.
    Towards understanding the loss of response to infliximab in patients with inflammatory bowel disease: A population PK modelling approach.
    26th Population Approach Group Europe (PAGE), Budapest, Hungary, 06-09 June 2017.
    PAGE 26: 7315 [www.page-meeting.org/?abstract=7315], (2017).

  • L. Klopp-Schulze, M. Joerger, S.L.W. Koolen, P. Neven, R.H.J. Mathijssen, C. Kloft.
    Exploring and explaining variability in tamoxifen and endoxifen pharmacokinetics in breast cancer patients: A pooled analysis.
    26th Population Approach Group Europe (PAGE), Budapest, Hungary, 06-09 June 2017.
    PAGE 26: 7314 [www.page-meeting.org/?abstract=7314], (2017).

  • S. Stübler, C. Kloft, W. Huisinga.
    Towards a systems biology model for inflammatory bowel disease.
    26th Population Approach Group Europe (PAGE), Budapest, Hungary, 06-09 June 2017.
    PAGE 26: 7130 [www.page-meeting.org/default.asp?abstract=7134], (2017).

  • J. Knöchel, C. Kloft, W. Huisinga.
    A novel measure of importance of state variables for model reduction: results for the blood coagulation network.
    26th Population Approach Group Europe (PAGE), Budapest, Hungary, 06-09 June 2017.
    PAGE 26: 7150 [www.page-meeting.org/default.asp?abstract=7150], (2017).

  • N. Hartung, C. Hethey, E. Goebgen, C. Kloft, W. Huisinga.
    Quantifying adaptive resistance in bacteria using well-designed dynamic time-kill curve experiments.
    26th Population Approach Group Europe (PAGE), Budapest, Hungary, 06-09 June 2017.
    PAGE 26: 7210 [www.page-meeting.org/default.asp?abstract=7210], (2017).

  • F.W. Ojara, A. Henrich, M. Joerger, C. Kloft.
    Evaluating predictors of paclitaxel-associated peripheral neuropathy: a pharmacodynamic modelling approach.
    6th International Pharmaceutical Federation Pharmaceutical Sciences World Congress (FIP PSWC), Uppsala/Stockholm, Sweden, 19-24 May 2017.
    https://www.fip.org/abstracts?page=abstracts&action=item&item=18157; http://pswc2017.fip.org/ysc_programme, (2017).

  • E.B. Goebgen, S.G. Wicha, C. Kloft.
    A semi-mechanistic PK/PD model to elucidate levofloxacin-induced killing and resistance development of escherichia coli.
    6th International Pharmaceutical Federation Pharmaceutical Sciences World Congress (FIP PSWC), Uppsala/Stockholm, Sweden, 19-24 May 2017.
    https://www.fip.org/abstracts?page=abstracts&action=item&item=18120; http://pswc2017.fip.org/ysc_programme, (2017).

  • I.K. Minichmayr, S.G. Wicha, C. Kloft.
    Comparative pharmacokinetic/pharmacodynamic target attainment of standard vs. intensified dosing for linezolid against S. aureus in plasma and interstitial fluid of sepsis patients.
    International Society of Antiinfective Pharmacology-European Society for Clinical Microbiology and Infectious Diseases, PK/PD of Anti-Infectives Study Group
    (ISAP-EPASG) conference, Vienna, Austria, 21 April 2017.

  • I.K. Minichmayr, S.G. Wicha, C. Kloft.
    Target-site specific pharmacokinetic/pharmacodynamic index values predicting linezolid efficacy in interstitial tissue space.
    27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria, 22-25 April 2017.
    https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=41950, (2017).

  • I.K. Minichmayr, O. Frey, A. Brinkmann, A. Roehr, J.A. Roberts*, C. Kloft* (*equal contr.)
    Development and validation of a dosing nomogram for continuous infusion of meropenem in critically ill patients
    27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria, 22-25 April 2017.
    https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=41918, (2017).

  • E.B. Goebgen, J. Seeger, A. Schaeftlein, C. Kloft.
    Levofloxacin in resistant Escherichia coli: is there a difference between 750 mg once a day and 500 mg twice a day?
    27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria, 22-25 April 2017.
    https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=40622, (2017).

  • F. Kluwe, C. Kirbs, L. Ehmann, F. Drescher, J. Weiss, P. Matzneller, M. Zeitlinger, C. Kloft.
    Target-site pharmacokinetics of voriconazole during sequence therapy.
    27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria, 22-25 April 2017.
    https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=42350, (2017).

  • L. Ehmann, M. Zoller, I.K. Minichmayr, C. Scharf, M. Vogeser, L. Frey, J. Zander, C. Kloft.
    Target attainment of standard meropenem dosing in critically ill patients: High impact of renal function.
    27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria, 22-25 April 2017.
    https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=42266, (2017).

  • L. Botermann, K. Monzel, K. Krueger, C. Eickhoff, A. Wachter, K. Kloft, U. Laufs, M. Schulz Evaluating patients’ comprehensibility of a standardised medication plan.
    83rd Annual meeting, the German Cardiac Society, Mannheim, Germany, 19-22 April 2017.
    Abstract book, Page 377 (2017).

  • A.M. Grisic, W. Huisinga, W. Reinisch, C. Kloft.
    Dosing infliximab in Crohn’s disease: Is adjustment for body size justified?
    12th Congress of European Crohn’s and Colitis Organisation (ECCO), Barcelona, Spain, 15-18 February 2017.
    https://academic.oup.com/ecco-jcc/article/2961428/P485
    doi: 10.1093/ecco-jcc/jjx002.609.

  • L. Botermann, K. Monzel, K. Krüger, C. Eickhoff, A. Wachter, U. Laufs, C. Kloft, M. Schulz.
    Evaluating internal medicine patients’ comprehensibility of a standardized medication plan.
    10th Pharmaceutical Care Network Europe (PCNE) Working Conference 2017, Bled, Slovenia, 01–03 February 2017.
    Int. J. Clin. Pharm. 39: 616 (2017).
    doi: 10.1007/s11096-017-0462-2

  • J. Melin, T. Truong, P. Hindmarsh, Z.P. Parra-Guillen, C. Kloft.
    Pharmacokinetic/pharmacodynamics analysis of hydrocortisone in pediatric patients with congenital adrenal hyperplasia.
    7th American Conference on Pharmacometrics (ACoP), Bellevue, Washington, USA, 23-26 October 2016.
    J. Pharmacokinet. Pharmacodyn. 43 (Suppl.): S27 (2016).
    doi:10.1007/s10928-016-9485-x

  • E.B. Goebgen, N. Hartung, J. Seeger, A. Schäftlein, C. Kloft.
    Treatment of catheterised ICU patients with levofloxacin - How in silico models help to streamline in vitro investigations of treatment efficacy at the target site.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Munich, Germany, 04-07 October 2016.
    www.dphg.de/fileadmin/downloads/DPhG2016_ConferenceBook_final.pdf, 121, (2016).

  • C. Weiser, M. Zeitlinger, C. Kloft.
    Does pre-coating of probes enable in vitro and in vivo microdialysis investigation of anidulafungin?
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Munich, Germany, 04-07 October 2016.
    www.dphg.de/fileadmin/downloads/DPhG2016_ConferenceBook_final.pdf, 120, (2016).

  • T. Richter, L. Klopp-Schulze, A. Lintermans, K. Van Asten, L. Jongen, C. Blomme, A. Poppe, P. Neven, M. Joerger, C. Kloft.
    Identification of clinically relevant patient factors on the pharmacokinetics of tamoxifen based on study data of two clinical trials: Exploratory data analysis
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Munich, Germany, 04-07 October 2016.
    www.dphg.de/fileadmin/downloads/DPhG2016_ConferenceBook_final.pdf, 107, (2016).

  • J. Seeger, E.B. Goebgen, C. Kloft.
    The effect of levofloxacin 500 mg bid and 750 mg qd against resistant Escherichia coli in the in vitro dynamic infection model.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Munich, Germany, 04-07 October 2016.
    www.dphg.de/fileadmin/downloads/DPhG2016_ConferenceBook_final.pdf, 172, (2016).

  • E.B. Goebgen, C. Kloft.
    Preventing new resistance development in antibiotic therapy: Which concentration of levofloxacin should Escherichia coli be exposed to?
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Munich, Germany, 04-07 October 2016.
    www.dphg.de/fileadmin/downloads/DPhG2016_ConferenceBook_final.pdf, 171, (2016).

  • A. Henrich, M. Joerger, W. Huisinga, C. Kloft, Z.P. Parra-Guillen.
    Characterisation of bone marrow exhaustion and long-term neutropenia by applying PK/PD modelling.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Munich, Germany, 04-07 October 2016.
    www.dphg.de/fileadmin/downloads/DPhG2016_ConferenceBook_final.pdf, 119, (2016).

  • S. Stuebler, C. Kloft, W. Huisinga.
    Towards a systems biology model of inflamatory bowel disease.
    German conference on Bioinformatics (GCB), Berlin, Germany, 12-15 September 2016.
    www.gcb2016.de/download/The%20Guide%20to%20GCB2016-with.pdf.

  • L. Klopp-Schulze, M. Joerger, S.G. Wicha, Z.P. Parra-Guillen, C. Kloft.
    Pharmacokinetic modelling of tamoxifen and endoxifen: Which factors are responsible for sub-therapeutic concentration?
    Annual Meeting of the Central European Society of Anticancer Drug Research (CESAR), Munich, Germany, 08-10 September 2016.
    Abstractbook, 21, (2016).

  • A. Henrich, M. Joerger, W. Huisinga, Z.P. Parra-Guillen, C. Kloft.
    Semi-mechanistic PK/PD modelling to characterise long-term deterioration of neutropenia in cancer patients.
    Annual Meeting of the Central European Society of Anticancer Drug Research (CESAR), Munich, Germany, 08-10 September 2016.
    Abstractbook, 16, (2016).

  • L. Botermann, K. Monzel, K. Krueger, C. Eickhoff, A. Wachter, C. Kloft, U. Laufs, M. Schulz.
    Comprehensibility of a standardized medication plan.
    76th World Congress of Pharmacy and Pharmaceutical Sciences (FIP). Buenos Aires, Argentina, 28 August-01 September 2016.
    http://www.fip.org/abstracts?page=abstracts&action=item&item=17186.

  • S. Fuhrmann, C. Kloft, W. Huisinga.
    Generic PBPK model to predict preclinial and clinical PK of antibodies.
    25th Population Approach Group Europe (PAGE), Lisbon, Portugal, 07-10 June 2016. PAGE 25:5749 [http://www.page-meeting.org/default.asp?abstract=5749], (2016).

  • Z.P. Parra-Guillen, M. Joerger, B. Berger, M. Haschke, C. Kloft.
    Pharmacokinetic analysis of midazolam and caffeine as probe drugs for cytochrome phenotyping in erlotinib treatment.
    25th Population Approach Group Europe (PAGE), Lisbon, Portugal, 07-10 June 2016. PAGE 25: 6005 [www.page-meeting.org/?abstract=6005], (2016).

  • L. Klopp-Schulze, M. Joerger, S.G. Wicha, Z.P. Parra-Guillen, C. Kloft.
    Tamoxifen and endoxifen pharmacokinetics: Exploration of differences in model performance using simulations.
    25th Population Approach Group Europe (PAGE), Lisbon, Portugal, 07-10 June 2016. PAGE 25: 5917 [www.page-meeting.org/?abstract=5917], (2016).

  • C. Hethey, S.G. Wicha, C. Kloft, W. Huisinga.
    Impact of the intracellular ribosomal concentration on in vitro bacterial growth kinetics and the antibacterial effect of linezolid on S. aureus in time-kill assays.
    25th Population Approach Group Europe (PAGE), Lisbon, Portugal, 07-10 June 2016. PAGE 25: 5705 [www.page-meeting.org/?abstract=5705], (2016).

  • J. Melin, Z.P. Parra-Guillen, N. Hartung, W. Huisinga, R.J. Ross, M.J. Whitaker, C. Kloft.
    Semi-mechanistic modelling of the nonlinear hydrocortisone pharmacokinetics to enable extrapolation into paediatric patients.
    25th Population Approach Group Europe (PAGE), Lisbon, Portugal, 07-10 June 2016. PAGE 25: 5764 [www.page-meeting.org/?abstract=5764], (2016).

  • J. Melin, S. Prothon, C. Kloft, A. Cleton, C. Johansson, C. Jorup, B. Olsson, U. Wählby Hamrén.
    Pharmacokinetics of the inhaled selective glucocorticoid receptor modulation AZD5423 following inhalation using different devices.
    25th Population Approach Group Europe (PAGE), Lisbon, Portugal, 07-10 June 2016. PAGE 25: 5908 [www.page-meeting.org/?abstract=5908], (2016).

  • A. Henrich, M. Joerger, S. Kraff, U. Jaehde, W. Huisinga, C. Kloft, Z.P. Parra-Guillen.
    PK/PD model extension to characterise bone marrow exhaustion in cancer patient making use of a prior paclitaxel PK model.
    25th Population Approach Group Europe (PAGE), Lisbon, Portugal, 07-10 June 2016. PAGE 25: 5879 [www.page-meeting.org/?abstract=5879], (2016).

  • L. Ehmann, M. Zoller, I.K. Minichmayr, C. Scharf, L. Frey, M. Vogeser, Huisinga W., J. Zander, C. Kloft.
    Pharmacokinetics of meropenem in critically ill patients with varying renal function.
    25th Population Approach Group Europe (PAGE), Lisbon, Portugal, 07-10 June 2016. PAGE 25: 5771 [www.page-meeting.org/?abstract=5771], (2016).

  • V.K. Schubert, C. Heyde, A. Sleinitz, C. Kloft.
    Entlassmanagement - Analyse des Entlassprozesses in den Ruppiner Kliniken.
    41. Wissenschaftlicher Kongress und Mitgliederversammlung, Aachen, Germany, 02-04 June 2016.
    www.adka.de/solva_docs/ADKAPosterAachen2016_63.pdf, (2016).

  • C. Weiser, T. Fuhrmann-Selter, C. Kloft.
    Development of a dynamic in vitro microdialysis system.
    8th International Symposium on Microdialysis, Uppsala, Sweden, 25-27 May 2016.
    https://reg.akademikonferens.se/app/Data/ProjectImages/6879/microdialysis2016-abstracts.pdf, 41, (2016).

  • D. Burau, P. Simon, L. Ehmann, D. Petroff, H. Wrigge, C. Kloft.
    Is relative recovery influenced by drug combinations?
    8th International Symposium on Microdialysis, Uppsala, Sweden, 25-27 May 2016.
    https://reg.akademikonferens.se/app/Data/ProjectImages/6879/microdialysis2016-abstracts.pdf, 42, (2016).

  • S. Schroepf, D. Burau, H.-G. Muench, H. Derendorf, C. Kloft.
    Microdialysis for therapeutic drug monitoring in infants.
    8th International Symposium on Microdialysis, Uppsala, Sweden, 25-27 May 2016. https://reg.akademikonferens.se/app/Data/ProjectImages/6879/microdialysis2016-abstracts.pdf, 29, (2016).

  • P. Simon, D. Petroff, D. Burau, L. Ehmann, C. Nestler, A. Dietrich, A.W. Reske, C. Kloft, M. Zeitlinger, F. Kees, H. Wrigge.
    Agreement of double measurements when determining soft tissue concentrations of linezolid in normal weight and morbidly obese patients by microdialysis.
    8th International Symposium on Microdialysis, Uppsala, Sweden, 25-27 May 2016.
    https://reg.akademikonferens.se/app/Data/ProjectImages/6879/microdialysis2016-abstracts.pdf, 43, (2016).

  • L. Botermann, K. Monzel, K. Krueger, C. Eickhoff, A. Wachter, C. Kloft, U. Laufs, M. Schulz.
    Assessment of the understandability of a standardized medication plan by patients with chronic heart failure.
    European Society of Cardiology - Heart Failure 2016, Florence, Italy, 21-24 May 2016.
    Eur. J. Heart Failure 18 (Suppl. s1): 235-236 (2016).
    doi:10.1002/ejhf.539

  • M. Zoller, L. Ehmann, C. Scharf, I.K. Minichmayr, M. Vogeser, L. Frey, C. Kloft, J. Zander.
    Meropenemspiegel in der initialen Therapiephase bei kritisch kranken Patienten.
    Deutscher Anästhesie Congress (DAC), Leipzig, Germany, 14-16 April 2016.
    Kongressführer, WV 4.1, (2016).

  • I.K. Minichmayr, M. Zeitlinger, P. Matzneller, C. Kloft.
    Population pharmacokinetics of ceftaroline in healthy volunteers – comparison of target attainment achieved by standard versus intensified dosing.
    26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Amsterdam, Netherlands, 09-12 April 2016. www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=32427, (2016).

  • I.K. Minichmayr, S.G. Wicha, C. Kloft
    AUC/MIC versus T>MIC: Which PK/PD index is more indicative of linezolid efficacy in plasma and interstitial tissue space of septic patients with different weight?
    26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Amsterdam, Netherlands, 9-12 April 2016. www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=32370, (2016).

  • C. Weiser, S.G. Wicha, M. Zeitlinger, C. Kloft
    Microdialysis of highly adsorbing drugs: Evaluation of a probe coating approach exemplified by anidulafungin.
    26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Amsterdam, Netherlands, 09-12 April 2016.
    https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=34684, (2016).

  • L. Ehmann, M. Zoller, C. Scharf, I.K. Minichmayr, M. Vogeser, L. Frey, J. Zander, C. Kloft.
    Pharmacokinetic/pharmacodynamic analysis of meropenem in critically ill patients.
    26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Amsterdam, Netherlands, 09-12 April 2016.
    https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=32417, (2016).

  • E.B. Goebgen, C.Kloft.
    Use of a dynamic in vitro infection model as link between in silico and in vivo: Is the standard dose of levofloxacin sufficient to treat septic patients with resistant Escherichia coli?
    26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Amsterdam, Netherlands, 09-12 April 2016.
    www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=30543, (2016).

  • N. Hartung, C. Huynh, C. Gaudy-Marqueste, A. Flavian, M.A. Richard, J.J. Grob, F. Hubert.
    Mathematical modelling of B-RAF inhibitor treatment for metastatic melanoma: Linking metastatic growth kinetics to clinical outcome.
    Present challenges of mathematics in oncology and biology of cancer, Marseille, France, 07-11 December 2015.
    https://www.i2m.univ-amu.fr/~fhubert/DONNEES/CIRM15/mcc2015.pdf, 54, (2015).

  • D. Burau, C. Weiser, C. Kloft.
    Erreichen Patienten effektive Konzentrationen von Antiinfektiva am Wirkort? Ein multidisziplinärer Beitrag zur Arzneimitteltherapiesicherheit bei Infektionskrankheiten.
    Jahrestagung der Deutschen Gesellschaft für Klinische Pharmazie (DGKlinPha), Leipzig, Germany, 14-15 November 2015.
    S. 3, Med. Monatsschr. Pharm. 39, Jahrgang 1/2016.

  • A. Sharma, B. Weber, P. Stopfer, M. Schmid, B. Rapp, J.M. Borghardt, C. Hallmann, P. Moroni-Zentgraf.
    Tiotropium pharmacokinetics in patients with asthma: a pooled analysis.
    Global Conference on Clinical Pharmacy of the American College of Clinical Pharmacy (ACCP), San Francisco, California, 17-21 October 2015.
    http://onlinelibrary.wiley.com/doi/10.1002/cpdd.216/pdf, 28-29, (2015).

  • L. Botermann, K. Krueger, C. Eickhoff, C. Kloft, M. Schulz.
    Patients’ understanding of administering information regarding food intake.
    World Congress of the International Pharmaceutical Federation (FIP), Düsseldorf, Germany, 29 September-03 October 2015.
    www.fip.org/abstracts?page=abstracts&action=item&item=11667, (2015).

  • M. Joerger, J. von Pawel, S. Kraff, J.R. Fischer, T. Gauler, L. Mueller, N. Reinmuth, M. Reck, M. Kimmich, M. Frank, H.G. Kopp, D. Behringer, Y.D. Ko, H. Ralf, M. Roessler, C. Kloft, A. Henrich, B. Moritz, U. Jaehde.
    Pharmacokinetically (PK)-guided dosing of paclitaxel in combination with carboplatin in advanced non-small cell lung cancer (NSCLC) is gender dependent: Updated results of the randomized CEPAC-TDM study.
    The European Cancer Congress 2015, Vienna, Austria, 25-29 September 2015.
    http://scientific.sparx-ip.net/ecco2015/#/page/646-647/dp, 51, (2015).

  • L. Ehmann, J. Zander, M. Zoller, C. Scharf, I.K. Minichmayr, C.Kloft.
    Variability of meropenem serum concentrations in intensive care patients.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Düsseldorf, Germany, 23-25 September 2015.
    www.dphg.de/fileadmin/downloads/DPhG2015_ConferenceBook_final.pdf, 194, (2015).

  • C. Weiser, M. Zeitlinger, C. Kloft.
    A new approach for in vitro microdialysis of anidulafungin.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Düsseldorf, Germany, 23-25 September 2015.
    www.dphg.de/fileadmin/downloads/DPhG2015_ConferenceBook_final.pdf, 141, (2015).

  • I.K. Bartels, E.B. Goebgen, C. Kloft.
    Dynamic in vitro infection model enables mimicking of in vivo levofloxacin PK profiles showing eradication of E. coli infection.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Düsseldorf, Germany, 23-25 September 2015.
    www.dphg.de/fileadmin/downloads/DPhG2015_ConferenceBook_final.pdf, 184, (2015).

  • E.B. Goebgen, S.G. Wicha, C. Kloft.
    Rapid bacterial cell counting method: proof-of-principle with a batch culture of E. coli.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Düsseldorf, Germany, 23-25 September 2015.
    www.dphg.de/fileadmin/downloads/DPhG2015_ConferenceBook_final.pdf, 192, (2015).

  • D. Burau, M.-A. Fuertig, S. Schröpf, C. Kloft.
    Optimisation of microdialysis of vancomycin in neonates by in vitro experiments.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Düsseldorf, Germany, 23-25 September 2015.
    www.dphg.de/fileadmin/downloads/DPhG2015_ConferenceBook_final.pdf, 186, (2015).

  • M.-A. Fuertig, D. Burau, C. Kloft.
    Development of an LC-MS/MS method to investigate the pharmacokinetics of antibiotics
    and concomitant drugs given to neonates suffering from sepsis.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Düsseldorf, Germany, 23-25 September 2015.
    www.dphg.de/fileadmin/downloads/DPhG2015_ConferenceBook_final.pdf, 139, (2015).

  • S.G. Wicha, R. Mundkowski, A. Klock, U. Wittel, U. Wellner, T. Keck, C. Kloft.
    Suitability of moxifloxacin to treat pancreatic infections from a pharmacokinetic perspective.
    55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, USA, 17-21 September 2015.
    www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=166a3120-886a-42a5-9032-7680c3e850cc&cKey=b704e76b-11c9-4024-9449-f40376925236&mKey=7a574a80-eab1-4b50-b343-4695df14907e, (2015).

  • A. Henrich, M. Joerger, W. Huisinga, C. Kloft, Z. P. Parra-Guillen.
    Dose-individualisation of paclitaxel in patients with advanced non-small cell lung cancer: exploiting modelling and simulation to refine dosing algorithm.
    Annual Meeting of the Central European Society of Anticancer Drug Research (CESAR), Innsbruck, Austria, 17-19 September 2015.
    http://link.springer.com/article/10.1007/s12254-015-0224-6, 51, (2015).

  • L. Klopp-Schulze, M. Joerger, Z. P. Parra-Guillen, C. Kloft.
    Making use of modelling and simulations: Towards individualised tamoxifen therapy in breast cancer.
    Annual Meeting of the Central European Society of Anticancer Drug Research (CESAR), Innsbruck, Austria, 17-19 September 2015.
    http://link.springer.com/article/10.1007/s12254-015-0224-6, 40, (2015).

  • C. Hethey, C. Kloft, W. Huisinga.
    Mechanism based pharmacodynamic modeling of growth inhibition in bacteria.
    6th Congress of European Microbiologists (Federation of European Microbiological Scientists, FEMS), Maastricht, Netherlands, 07-11 June 2015.
    FEMS 6: 1409 [http://fems-microbiology.kenes.com/Documents/FEMS%20abstracts.pdf], (2015).

  • S. Fuhrmann, C. Kloft, W. Huisinga.
    Effect of mouse model immunity on antibody distribution.
    24th Population Approach Group Europe (PAGE), Hersonissos, Greece, 02-05 June 2015.
    PAGE 24: 3613 [www.page-meeting.eu/default.asp?abstract=3613], (2015).

  • J. Knöchel, S. Gopalakrishnan, C. Kloft, W. Huisinga.
    Impact of randomness of mutation dynamics on the development of drug resistance under antiviral therapy.
    24th Population Approach Group Europe (PAGE), Hersonissos, Greece, 02-05 June 2015.
    PAGE 24: 3544 [www.page-meeting.eu/default.asp?abstract=3544], (2015).

  • C. Hethey, C. Kloft, W. Huisinga.
    Mechanism-based pharmacodynamics modelling of bacterial growth inhibition by antibiotics.
    24th Population Approach Group Europe (PAGE), Hersonissos, Greece, 02-05 June 2015.
    PAGE 24: 3464 [www.page-meeting.eu/default.asp?abstract=3464], (2015).

  • A. Henrich, M. Joerger, W. Huisinga, C. Kloft, Z. P. Parra-Guillen.
    External evaluation of a PK/PD model describing the time course of paclitaxel and eutropenia in patients with advanced non-small cell lung cancer.
    24th Population Approach Group Europe (PAGE), Hersonissos, Greece, 02-05 June 2015.
    PAGE 24: 3460 [www.page-meeting.eu/default.asp?abstract=3460], (2015).

  • J. Melin, B.L. Olsson, C. Johansson, C. Kloft, U. Wählby Hamrén.
    Population pharmacokinetic analysis of AZD4818 in healthy volunteers following three different routes of administration.
    24th Population Approach Group Europe (PAGE), Hersonissos, Greece, 02-05 June 2015.
    PAGE 24: 3570 [www.page-meeting.org/default.asp?abstract=3570], (2015).

  • L. Klopp-Schulze, M. Joerger, Z.P. Parra-Guillen, C. Kloft.
    In silico simulation study: A comparison of two population pharmacokinetic models of tamoxifen and its major metabolite endoxifen.
    24th Population Approach Group Europe (PAGE), Hersonissos, Greece, 02-05 June 2015.
    PAGE 24: 3447 [www.page-meeting.org/default.asp?abstract=3447], (2015).

  • I.K. Minichmayr, M. Zeitlinger, A. Schaeftlein, C. Kloft.
    Pharmacokinetic-pharmacodynamic target attainment of intravenous linezolid regimens in plasma and peripheral tissue fluids of four distinct populations.
    24th Population Approach Group Europe (PAGE), Hersonissos, Greece, 02-05 June 2015.
    PAGE 24: 3482 [www.page-meeting.org/?abstract=3482], (2015).

  • S.G. Wicha, M.G. Kees, A. Solms, I.K. Minichmayr, A. Kratzer, C. Kloft.
    TDMx: A web-application for therapeutic drug monitoring enhanced by pharmacometrics.
    24th Population Approach Group Europe (PAGE), Hersonissos, Greece, 02-05 June 2015.
    PAGE 24: 3622 [www.page-meeting.org/?abstract=3622], (2015).

  • S.G. Wicha, A. Solms, W. Huisinga, C. Kloft.
    Evaluation of the delta-method to efficiently compute probability of target attainment of antibiotics.
    24th Population Approach Group Europe (PAGE), Hersonissos, Grece, 02-05 June 2015.
    PAGE 24: 3445 [www.page-meeting.eu/default.asp?abstract=3445], (2015).

  • J.M. Borghardt, B. Weber, A. Staab, C. Kloft.
    A new parameterisation to describe parallel absorption processes after drug inhalation.
    24th Population Approach Group Europe (PAGE), Hersonissos, Grece, 02-05 June 2015.
    PAGE 24: 3607 [www.page-meeting.org/default.asp?abstract=3607], (2015).

  • B. Weber, J.M. Borghardt.
    New insights in the Pulmonary Fate of Inhaled Drugs.
    24th Population Approach Group Europe (PAGE), Hersonissos, Grece, 02-05 June 2015.
    PAGE 24: 3327 [www.page-meeting.org/default.asp?abstract=3327], (2015).

  • H. Edlund, C. Steenholdt, M. Ainsworth, J. Brynskov, O.Ø. Thomsen, W. Huisinga, C. Kloft.
    Covariate analysis of infliximab in Crohn’s disease using available PK models as prior.
    24th Population Approach Group Europe (PAGE), Hersonissos, Greece, 02-05 June 2015.
    PAGE 24: 3380 [www.page-meeting.org/?abstract=3380], (2015).

  • S.G. Wicha, A. Kratzer, C. Kloft.
    TDMx: Eine Web-Applikation zur Dosierungsoptimierung von Antiinfektiva.
    40th Congress of the German Association of Hospital Pharmacists (ADKA), Mannheim, Germany, 28-30 Mai 2015.
    www.adka.de/solva_docs/ADKAPosterMannheim2015_08.pdf, (2015).

  • C. Steenholdt, H. Edlund, M. Ainsworth, J. Brynskov, O.Ø. Thomsen, W. Huisinga, C. Kloft.
    Relationship between measures of infliximab exposure and clinical outcome of infliximab intensification at therapeutic failure in Crohn’s disease.
    Digestive Disease Week 2015 (DDW2015), Washington DC, USA, 16-19 May 2015.
    Gastroenterology, 148 (Suppl.): S848 (2015).

  • I.K. Minichmayr, T. Steinke, S. Moritz, S. Beck, S.G. Wicha, M.G. Kees, C. Kloft.
    Determinants of piperacillin clearance in critically ill patients receiving continuous infusion: Comparison of cystatin C-based and alternative markers of renal function.
    25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, 25-28 April 2015.
    www.escmid.org/escmid_library/online_lecture_library/material/?mid=23599, (2015).

  • E. Goebgen, S.G. Wicha, C. Kloft.
    Assessing the antibiotic effect with a simple, rapid and reliable quantification assay for counting clinically relevant strains with a CASY coulter counter.
    25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, 25-28 April 2015.
    www.escmid.org/escmid_library/online_lecture_library/material/?mid=26038, (2015).

  • S.G. Wicha, M.G. Kees, A. Solms, I.K. Minichmayr, A. Kratzer, C. Kloft.
    TDMx: A web application for bedside model-supported therapeutic drug monitoring to improve antibiotic therapy.
    25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, 25-28 April 2015.
    www.escmid.org/escmid_library/online_lecture_library/material/?mid=29246, (2015).

  • S.G. Wicha, E. Goebgen, J. Kuss, C. Kloft.
    Growth state at drug exposure highly influences the pharmacodynamics of linezolid, levofloxacin, meropenem and vancomycin in time-kill studies with Staphylococcus aureus.
    25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, 25-28 April 2015.
    www.escmid.org/escmid_library/online_lecture_library/material/?mid=29180, (2015).

  • C. Weiser, M. Zeitlinger, C. Kloft.
    In vitro microdialysis of anidulafungin as prerequisite for an in vivo microdialysis study.
    25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, 25-28 April 2015.
    www.escmid.org/escmid_library/online_lecture_library/material/?mid=29161, (2015).

  • R. Schwameis, P. Matzneller, Z. Oesterreicher, A. Appelt, D. Burau, C. Kloft, M. Zeitlinger.
    Synovial fluid concentrations of cefuroxime and linezolid after surgical interventions.
    25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, 25-28 April 2015.
    www.escmid.org/escmid_library/online_lecture_library/material/?mid=23649, (2015).

  • Z. Oesterreicher, M. Zeitlinger, D. Burau, C. Kloft, R. Schwameis.
    Plasma und Synovialflüssigkeit Pharmakokinetik von Cefuroxim und Linezolid in Patienten mit elektiver Kniearthroskopie nach intravenöser single dose Applikation- eine explorative Studie.
    9. Österreichischer Infektionskongress, Saalfelden, Austria, 15-18 April 2015.

  • C. Steenholdt, H. Edlund, M. Ainsworth, J. Brynskov, O.Ø. Thomsen, W. Huisinga, C. Kloft.
    Relationship between measures of infliximab exposure and clinical outcome of infliximab intensification at therapeutic failure in Crohn’s disease.
    10th European Crohn’s and Colitis Organisation (ECCO) conference, Barcelona, Spain, 18-21 February 2015.
    ECCO 10: P501 [www.ecco-ibd.eu/index.php/publications/congress-abstract-s/abstracts-2015/item/p501-relationship-between-measures-of-infliximab-exposure-and-clinical-outcome-of-infliximab-intensification-at-therapeutic-failure-in-crohnaposs-disease.html?highlight=YToxOntpOjA7czo3OiJlZGx1bmQyIjt9], (2015).

  • L. Botermann, N. Griese, K. Krueger, C. Eickhoff, M. Schulz, C. Kloft.
    Utilisation of electronically generated medication plans in German community pharmacies: status quo.
    43rd European Society of Clinical Pharmacy (ESCP) symposium on Clinical Pharmacy, Copenhagen, Denmark, 22-24 October 2014.
    Abstractbook, 76, (2014).

  • H. Andersson, A. Eser, W. Huisinga, W. Reinisch, C. Kloft.
    Recommendations for dose adjustments of infliximab in Crohn’s disease patients with higher clearance.
    5th American Conference on Pharmacometrics (ACoP), Las Vegas, Nevada, USA, 12-15 Oct 2014.
    J. Pharmacokinet. Pharmacodyn., 41 (Suppl.): S27 (2014).

  • Z. Parra-Guillen, B. Weber, A. Sharma, J. Freijer, J.M. Borghardt, S. Retlich, I.F. Troconiz.
    Population pharmacokinetic analysis of tiotropium in healthy volunteers after intravenous administration and inhalation.
    5th American Conference on Pharmacometrics (ACoP), Las Vegas, Nevada, USA, 12-15 Oct 2014.
    J. Pharmacokinet. Pharmacodyn., 41 (Suppl.): S54 (2014).

  • L. Botermann, N. Griese, K. Krueger, C. Eickhoff, M. Schulz, C. Kloft.
    Utilisation of electronically generated medication plans in German community pharmacies: status quo.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Frankfurt, Germany, 24-26 September 2014.
    Abstractbook, 151, (2014).

  • C. Weiser, D. Kauzor, H. Brosig, F. Kees, M. Zeitlinger, C. Kloft.
    HPLC method development and validation for the determination of anidulafungin in microdialysis samples of healthy volunteers and intensive care patients.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Frankfurt, Germany, 24-26 September 2014.
    Abstractbook, 148-149, (2014).

  • A.K. Appelt, D. Kauzor, S.G. Wicha, H. Brosig, M. Zeitlinger, C. Kloft
    HPLC method development for the determination of linezolid and cefuroxime in synovial fluidsite microdialysis samples of arthritis patients.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Frankfurt, Germany, 24-26 September 2014.
    Abstractbook, 170, (2014).

  • J.B. Borghardt, B. Weber, A. Staab, C. Kunz, J. Schiewe, C. Kloft.
    Systemic and pulmonary pharmacokinetics of inhaled olodaterol.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Frankfurt, Germany, 24-26 September 2014.
    Abstractbook, 196, (2014).

  • A. Henrich, Z. Parra-Guillen, C. Kloft.
    Comparison of three pharmacokinetic/toxicity models describing neutropenia caused by topotecan in cancer patients.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Frankfurt, Germany, 24-26 September 2014.
    Abstractbook, 136, (2014).

  • D. Kauzor, S. Schröpf, M. Fürtig, D. Ruhe, C. Kloft.
    In vitro microdialysis characterising vancomycin as precondition for an upcoming trial in neonates.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Frankfurt, Germany, 24-26 September 2014.
    Abstractbook, 149-150, (2014).

  • C. Kloft.
    Pharmacometrics – for better therapies?
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Frankfurt, Germany, 24-26 September 2014.
    Abstractbook, 20, (2014).

  • D. Kauzor, S. Spielmann, H. Brosig, O. Blankenstein, C. Kloft.
    Medication safety study investigating hydrocortisone in individually compounded capsules for paediatric use in congenital adrenal hyperplasia
    6th Conference of the European Paediatric Formulation Initiative (EUPFI), Athens, Greece, 17-18 September 2014, (2014)

  • I.K. Minichmayr, T. Steinke, S. Moritz, S. Beck, F. Kees, M.G. Kees, C. Kloft.
    Determinants of meropenem clearance in ICU patients receiving continuous infusion: value of cystatin C.
    54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA, 05-09 September 2014.

  • I.K. Minichmayr, A. Schaeftlein, M. Zeitlinger, C. Kloft.
    Pharmacometric analysis of clinical microdialysis data – Adequacy of standard linezolid dosing in different patient groups.
    Tag der Pharmazie of the Deutsche Pharmazeutische Gesellschaft (DPhG), Berlin, Germany, 04 July 2014.

  • A. Henrich, Z. Parra-Guillen, C. Kloft.
    Comparison of three PK/PD models for describing neutropenia in cancer patients treated with topotecan.
    Annual Meeting of the Central European Society of Anticancer Research (CESAR), Bonn, Germany, 26-28 June 2014.
    Abstractbook, 42, (2014).

  • S.G. Wicha, A. Solms, W. Huisinga, C. Kloft.
    Adaptive optimal design for the concentration tiers in time-kill curve experiments.
    23rd Population Approach Group Europe (PAGE), Alicante, Spain, 10-13 June 2014.
    PAGE 23: 3202 [http://www.page-meeting.eu/default.asp?abstract=3202], (2014).

  • J. Melin, P. Hindmarsh, W. Huisinga, C. Kloft.
    Population pharmacokinetic analysis of hydrocortisone in paediatric patients with adrenal insufficiency.
    23rd Population Approach Group Europe (PAGE), Alicante, Spain, 10-13 June 2014.
    PAGE 23: 3106 [http://www.page-meeting.eu/default.asp?abstract=3106], (2014).

  • J.B. Borghardt, B. Weber, A. Staab, C. Kunz, J. Schiewe, C. Kloft.
    The physiological interpretation of population pharmacokinetic modelling results for inhaled olodaterol.
    23rd Population Approach Group Europe (PAGE), Alicante, Spain, 10-13 June 2014.
    PAGE 23: 3245 [http://www.page-meeting.org/default.asp?abstract=3245], (2014).

  • I.K. Minichmayr, M. Zeitlinger, C. Kloft.
    Target site pharmacokinetics of doripenem in plasma and interstitial space fluid of peripheral tissues.
    23rd Population Approach Group Europe (PAGE), Alicante, Spain, 10-13 June 2014.
    PAGE 23: 3240 [http://www.page-meeting.eu/default.asp?abstract=3240], (2014).

  • Z. Parra.-Guillen, J.M Cendrós Carreras, C. Peraire, R. Obach, J. Prunynosa, Chetaille E, I.F. Trocóniz.
    Population pharmacokinetic modelling of irosustat in postmenopausal women with oestrogen-receptor positive breast cancer.
    23rd Population Approach Group Europe (PAGE), Alicante, Spain, 10-13 June 2014.
    PAGE 23: 3212 [http://www.page-meeting.eu/default.asp?abstract=3212], (2014).

  • C. Hethey, C. Kloft, W. Huisinga.
    Towards a cell-level model to predict bacterial growth under antimicrobial perturbation.
    23rd Population Approach Group Europe (PAGE), Alicante, Spain, 10-13 June 2014.
    PAGE 23: 3100 [www.page-meeting.org/?abstract=3100], (2014).

  • I.K. Minichmayr, A. Schaeftlein, M. Zeitlinger, C. Kloft.
    Impact of patient- and disease-related characteristics on plasma and target site pharmacokinetics of linezolid in four heterogeneous populations.
    24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona, Spain, 10-13 May 2014.
    Final Programme, 232, (2014).

  • S.G. Wicha, K. Zink, T. Haak, F. Kees, C. Kloft, M.G. Kees.
    Pharmacokinetic/pharmacodynamic analysis of moxifloxacin in patients with diabetic foot infections.
    24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona, Spain, 10-13 May 2014.
    Final Programme, 234, (2014).

  • S.G. Wicha, J. Kuss, W. Huisinga, C. Kloft.
    Semi-mechanistic PK/PD modelling of drug interactions between vancomycin or linezolid combined with meropenem against Staphylococcus aureus.
    24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona, Spain, 10-13 May 2014.
    Final Programme, 232, (2014).

  • A. Kratzer, U. Liebchen, S.G. Wicha, F. Kees, M.G. Kees.
    Protein binding of ertapenem in plasma from heatlhy volunteers and from ICU patients.
    24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona, Spain, 10-13 May 2014.
    Final Programme, 233, (2014).

  • D. Kauzor, S. Schröpf, C. Kloft.
    In vitro characterisation of vancomycin as a prerequisite for a microdialysis study in neonates.
    24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona, Spain, 10-13 May 2014.
    Final Programme, 232, (2014).

  • D. Kauzor, S.Spielmann, C. Kloft, O.Blankenstein
    Medication safety study investigating hydrocortisone individually and extemporaneously compounded capsules for paediatric use in congenital adrenal hyperplasia .
    16th European Conference of Endocrinology (ECE), Wroclaw, Poland, 03-07 May 2014, (2014).

  • C.A. Ritter, M. Michaelis, J. Cinatl jr., R.M. Mader, H. Fröhlich, W. Jäger, M. Joerger, U. Jaehde, C. Kloft.
    A systems pharmacology approach to investigate drug resistande in EGFR-prositive NSCLC: Establishing a CESAR network.
    7th Noordwijkerhout Symposium on Pharmacokinetics, Pharmacodynamics and Systems Pharmacology, Noordwijkerhout, The Netherlands, 23-25 April 2014.
    Abstractbook Part II, 177, (2014).

  • S.S. Allemann, J.W. Foppe van Mil, L. Botermann, K.U. Berger, N. Griese, K.E. Hersberger.
    Evolution of pharmaceutical care definitions: the PCNE definition 2013.
    Pharmaceutical Care Network Europe (PCNE) Working Symposium 2014, Sliema, Malta, 14-15 March 2014.
    Int. J. Clin. Pharm., 36: 847-857 (2014).

  • H. Andersson, A. Keunecke, A. Eser, W. Huisinga, W. Reinisch, C. Kloft.
    Pharmacokinetic considerations for optimising dosing regimens of infliximab in patients with Crohn's disease.
    9th European Crohn’s and Colitis Organisation (ECCO) conference, Copenhagen, Denmark, 20-22 Feb 2014.
    ECCO 9: DOP061 [https://www.ecco-ibd.eu/publications/congress-abstract-s/abstracts-2014/item/dop061-pharmacokinetic-considerations-for-optimising-dosing-regimens-of-infliximab-in-patients-with-crohn-s-disease.html], (2014).

  • Z.P. Parra-Guillen, P. Berraondo, E. Grenier, B. Ribba, I.F.Trocóniz.
    Mathematical model approach to describe tumour response elicited by immune-stimulatory based therapeutics in mice.
    35th European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms (EORTC-PAMM) winter meeting, Muenster, Germany, 12-15 February 2014.




  • C. Kloft I.
    Pharmacometrics and systems biology in oncology: is there an intersection?
    Int. J. Clin. Pharmacol. Ther., 51: 89-90 (2013).




  • I. Minichmayr, V. Nock, U. Jaehde, C. Kloft.
    Thrombocytopenia following high-dose chemotherapy with carboplatin, etoposide and thiotepa in patients with testicular germ cell cancer.
    Int. J. Clin. Pharmacol. Ther., 51: 74-76 (2013).




  • V. Nock, A. Lindauer, U. Jaehde, C. Kloft.
    Prediction of cytotoxic drug concentrations occurring on the day of autologous stem cell rescue during chemotherapy with a high-dose regimen.
    Int. J. Clin. Pharmacol. Ther., 51: 38-40 (2013).

  • S.G. Wicha, W. Huisinga, C. Kloft
    Mechanism-based PK/PD modelling of antagonistic drug-drug interactions exemplified by linezolid and meropenem against S. aureus.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Freiburg, 09.-11.10.2013.
    [http://www.dphg2013.de/Tagungsband/DPhG_Meeting2013_ConferenceBook_Complete.pdf], 153, (2013).

  • D. Kauzor, O. Blankenstein, S. Spielmann, C. Kloft
    HPLC method development for the determination of hydrocortisone from capsules contributing to a drug? medication safety study.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Freiburg, Germany, 09.-11.10.2013.
    http://www.dphg2013.de/Tagungsband/DPhG_Meeting2013_ConferenceBook_Complete.pdf, 154, (2013).

  • G.V. Kalayda, M. Michaelis, J. Cinatl jr., R.M. Mader, H. Fröhlich, N.Sarin, J. Melin, F. Engel, W. Jäger, R. Frötschl, U. Jaehde, C. Kloft (6), C.A. Ritter.
    A systems pharmacology approach to improve drug therapy in NSCLC: Establishing a CESAR network.
    Annual Meeting of the Central European Society of Anticancer Research (CESAR), Tübingen, Germany, 27-29.06.2013.
    Abstract book: http://www.cesar.or.at/download/text/3085/Annual%20Meeting%20Abstract%20Book%202013_final%20Druckvorlage.pdf, 33, (2013)




  • H. Andersson, A. Keunecke, A. Eser, W. Reinisch, W. Huisinga, C. Kloft.
    Clinical relevance of albumin concentration in patients with Crohn’s disease treated with infliximab for recommendations on dosing regimen adjustments
    22nd PAGE meeting, Glasgow, UK. 11-14.06.2013
    Abstact IV-08: http://www.page-meeting.org/default.asp?abstract=2890




  • I.K. Minichmayr, A. Schaeftlein, M. Zeitlinger, C. Kloft.
    A microdialysate-based integrated model with nonlinear elimination for determining plasma and tissue pharmacokinetics of linezolid in four distinct populations.
    22nd PAGE meeting, Glasgow, UK. 11-14.06.2013.
    Abstact III-37: http://www.page-meeting.org/default.asp?abstract=2930




  • J. Borghardt, A. Staab, C. Kunz, J. Schiewe, C. Kloft.
    Characterisation of different absorption rate constants after inhalation of olodaterol.
    22nd Population Approach Group Europe (PAGE), Glasgow, Scotland, 11.-14.06.2013.
    PAGE 22: 2895 [www.page-meeting.org/?default.asp?abstract=2895], (2013).




  • A. Solms, A. Schäftlein, M. Zeitlinger, C. Kloft, W. Huisinga.
    Translating physiologically based parameterization and inter-individual variability into the analysis of population pharmacokinetics.
    22nd Population Approach Group Europe (PAGE), Glasgow, Scotland, 11.-14.06.2013.
    PAGE 22: 2844 [www.page-meeting.org/?abstract=2844], (2013).




  • C. Kirbs, C. Kloft.
    In vitro microdialysis of cytokines.
    7th International Symposium on Microdialysis, Poitiers, France, 23.-24.05.2013.
    Abstract 1.4 http://microdialysis.conference.univ-poitiers.fr/spip.php?article93&lang=en




  • S.G. Wicha, M.G. Kees, C. Kloft.
    In vitro time kill curve studies of linezolid and meropenem in combination against methicillin susceptible Staphylococcus aureus in different growth phases.
    23rd European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 27.-30.04.2013.
    [http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=163976&XNSPRACHE_ID=2&XNKONGRESS_ID=180&XNMASKEN_ID=900]




  • I.K. Minichmayr, A. Schaeftlein, M. Zeitlinger, C. Kloft.
    Population pharmacokinetics of linezolid in diabetic patients with soft tissue infections – are standard doses adequate?
    23rd European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 27.-30.04.2013.
    [http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=165625&XNSPRACHE_ID=2&XNKONGRESS_ID=180&XNMASKEN_ID=900]




  • M.G. Kees, S. Beck, F. Kees, J.W. Hilpert.
    Monitoring of urine concentrations of meropenem and piperacillin during continuous infusion: simpler than in plasma, yet quite as useful? (publication only)
    23rd European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 27.-30.04.2013.
    [http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=161588&XNSPRACHE_ID=2&XNKONGRESS_ID=180&XNMASKEN_ID=900]





  • M.G. Kees, F. Kees.
    Determination of protein binding of vancomycin by ultrafiltration requires strict standardisation of experimental conditions. (oral presentation)
    23rd European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 27.-30.04.2013.
    [http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=163094&XNSPRACHE_ID=2&XNKONGRESS_ID=180&XNMASKEN_ID=900]




  • L. Botermann, U. Laufs, N. Griese-Mammen, K. Krüger, M. Schulz, C. Kloft
    Medication plan – feasibility in daily practice.
    Int. J. Clin. Pharm. 35: 504 (2013)

  • R. Niebecker, C. Kloft.
    Modelling of anti-drug antibodies directed against a monoclonal antibody.
    21st Population Approach Group Europe (PAGE), Venice, Italy, 05.-08.06.2012.
    PAGE 21: 2432, [www.page-meeting.org/?abstract=2432], (2012).




  • Schaeftlein, A. Solms, M. Zeitlinger, W. Huisinga, C. Kloft.
    Microdialysate-corrected mid-interval model versus microdialysate-based integral model – Population pharmacokinetics of levofloxacin in peripheral tissues.
    21st Population Approach Group Europe (PAGE), Venice, Italy, 05.-08.06.2012.
    PAGE 21: 2359 [www.page-meeting.org/?abstract=2359], (2012).




  • Solms, A. Schaeftlein, M. Zeitlinger, W. Huisinga, C. Kloft.
    Using Population PBPK Modelling to interpret Population PK results exemplified for Levofloxacin in Plasma and Interstitial Fluid.
    21st Population Approach Group Europe (PAGE), Venice, Italy, 05.-08.06.2012.
    PAGE 21: 2350 [www.page-meeting.org/?abstract=2350], (2012).




  • V. Nock, D. Rüppel, C. Kloft.
    Comparison of three PK/PD models for glycated haemoglobin in diabetes type 2 patients treated with lixisenatide.
    21st Population Approach Group Europe (PAGE), Venice, Italy, 05.-08.06.2012.
    PAGE 21: 2335 [www.page-meeting.org/?abstract=2335], (2012).




  • V. Nock, A. Lindauer, U. Jaehde, C. Kloft.
    Optimal day for autologous stem cell rescue in a combination high-dose chemotherapy (HDCT) regimen in patients with testicular cancer.
    Annual Meeting of the Central European Society of Anticancer Research (CESAR), Essen, Germany, 28.-30.06.2012.
    Abstract book, www.cesar.or.at/download/text/2053/Annual Meeting 2012 Abstract Book_2012-08-07.pdf, 26 (2012).




  • I. Minichmayr, V. Nock , U. Jaehde, C. Kloft.
    Thrombocytopenia following high-dose chemotherapy with autologous stem cell retransfusion in patients with testicular cell cancer.
    Annual Meeting of the Central European Society of Anticancer Research (CESAR), Essen, Germany, 28.-30.06.2012.
    Abstract book, www.cesar.or.at/download/text/2053/Annual Meeting 2012 Abstract Book_2012-08-07.pdf, 59 (2012).




  • I. Minichmayr, C. Kloft.
    Pharmacometrics – methodologies, establishment and opportunities of a promising new discipline in Germany.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Greifswald, Deutschland, 11.-13.10.2012.
    [http://pharm1.pharmazie.uni-greifswald.de/pdf/Tagungsband.pdf], 068, (2012).

  • S.G. Wicha, C. Kloft.
    Evaluation of combinatory use of linezolid and meropenem against methicillin susceptible S. aureus by dynamic checkerboard testing.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Greifswald, Deutschland, 11.-13.10.2012.
    [http://pharm1.pharmazie.uni-greifswald.de/pdf/Tagungsband.pdf], 136, (2012).

  • E. Goebgen, S.G. Wicha, C. Kloft.
    Development of a simple, rapid and reliable assay to count enterococcus faecium with a CASY coulter counter to assess antibiotic therapy.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Greifswald, Deutschland, 11.-13.10.2012.
    [http://pharm1.pharmazie.uni-greifswald.de/pdf/Tagungsband.pdf], 137, (2012).

  • Schaeftlein, M. Kees, A. Heininger, C. Kloft.
    Standard doses of intravenous and enteral moxifloxacin provide insufficient drug exposure for nosocomial pneumonia in intensive care unit patients.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Greifswald, Deutschland, 11.-13.10.2012.
    [http://pharm1.pharmazie.uni-greifswald.de/pdf/Tagungsband.pdf], 177, (2012).




  • A. Heininger, F. Kees, H. Haeberle, M. G. Kees.
    Plasmaspiegel von intravenös und enteral appliziertem Moxifloxacin bei kritisch kranken Intensivpatienten
    Infection 40: S27-S28 (2012).

  • S. Weber, M.G. Kees, F. Kees, Th. Horbach.
    Pharmakokinetik von Moxifloxacin bei krankhaft adipösen Patienten.
    Infection 40: S35-S36 (2012).




  • M. Schmitz, E. Polykandriotis, M. Jost, M.G. Kees, F. Kees, R.E. Horch.
    Penetration von Moxifloxacin in das Wundgewebe und Wundexsudat, gewonnen während topisch negativer Druckbehandlung.
    Infection 40: S38-S39 (2012).

  • C. Justinger, O. Kollmar, M.G. Kees, F. Kees, M.K. Schilling.
    Penetration von Moxifloxacin in das Lebergewebe von Patienten mit Tumoren der Leber.
    Infection 40: S50-S51 (2012).

  • A. Schaeftlein, R. Keel, J.L. Kuti, C. Kloft.
    Lean body weight explains variability in clearance and absorption rate constant of linezolid in cystic fibrosis patients.
    21st European Congress of Clinical Microbiology and Infectious Diseases/International Congress of Chemotherapy, Milan, Italy, 07.-10.05.2011.
    Clin. Microbiol. Infect., 17 (Suppl. s4): P806 (2011).

  • C. Kirbs, F. Simmel, M. Zeitlinger, E. Lackner, C. Rimmbach, C. Kloft.
    Clinical long-term microdialysis study with voriconazole in healthy volunteers.
    21st European Congress of Clinical Microbiology and Infectious Diseases/International Congress of Chemotherapy, Milan, Italy, 07.-10.05.2011.
    Clin. Microbiol. Infect., 17 (Suppl. s4): S196 (2011).

  • A. Sleinitz, C. Heyde, C. Kloft.
    Verschreibungssoftware und Unit Dose - ein Gewinn für die Arzneimitteltherapiesicherheit! 36. Wissenschaftlicher Kongress, Berlin 12.-15.05.2011. Krankhauspharmazie 32: 304 (2011).




  • M. Frank, J.S. Van der Walt, A. Kunz, G. Harms, C. Kloft.
    Integrated population pharmacokinetic model development of nevirapine for mothers and newborns including healthy male volunteer data.
    20th Population Approach Group Europe (PAGE), Athens, Greece, 07.-10.06.2011.
    [www.page-meeting.org/?abstract=2273], (2011).




  • V. Nock, A. Lindauer, U. Jaehde, C. Kloft.
    Leukopenia following triple high-dose chemotherapy and stem cell rescue.
    20th Population Approach Group Europe (PAGE), Athens, Greece, 07.-10.06.2011.
    [www.page-meeting.org/?abstract=2156], (2011).




  • R. Niebecker, A. Drescher, C. Kloft.
    Importance of study design for estimation of Vmax and Km characterising nonlinear monoclonal antibody clearance.
    20th Population Approach Group Europe (PAGE), Athens, Greece, 07.-10.06.2011.
    [www.page-meeting.org/?abstract=2187], (2011).




  • A. Schaeftlein, R.A. Keel, J.L. Kuti, C. Kloft.
    Comparison of elimination and absorption pharmacokinetics of linezolid in cystic fibrosis patients by three nonlinear models.
    20th Population Approach Group Europe (PAGE), Athens, Greece, 07.-10.06.2011.
    [www.page-meeting.org/?abstract=2083], (2011).




  • V. Nock, A. Lindauer, U. Jaehde, C. Kloft.
    Understanding the time course of leukopenia in patients undergoing high-dose chemotherapy
    Annual Meeting of the Central European Society for Anticancer Research (CESAR), Greifswald, 16.-18.06.2011.
    [http://www.cesar.or.at/download/text/2032/CESAR Annual Meeting 2011 Abstract Book], (2011).




  • C. Kloft.
    Modelling of pharmacokinetics and biomarkers/patient characteristics of monoclonal antibodies in advanced carcinoma patients.
    Annual Meeting of the Central European Society for Anticancer Research (CESAR), Greifswald, 16.-18.06.2011.
    [http://www.cesar.or.at/download/text/2032/CESAR Annual Meeting 2011 Abstract Book], (2011).




  • M. von Kleist, M. Frank, C. Kloft, C. Schütte.
    A Mathematical Modelling Framework to Assess the Impact of Antiviral Strategies on HIV Transmission.
    8th European Conference on Mathematical and Theoretical Biology, and Annual Meeting of the Society for Mathematical Biology, Kraków, Poland, 28.06.-02.07.2011.
    Abstractband, 1010-1011, (2011).




  • C. Kirbs, A. Simm, C. Kloft.
    In vitro microdialysis of cytokines applying a validated cba/facs quantification method.
    9th Joint Meeting of the International Cytokine Society (ICS) and the International Society for Interferon and Cytokine Research (ISICR), Florence, Italy, 09.-12.10.2011.
    Cytokine, 56: 34 (2011).




  • M. Frank, J.S. Van der Walt, A. Kunz, G. Harms, C. Kloft.
    Investigation of absorption models for nevirapine in healthy males to support mother & newborn data.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG), Braunschweig, Deutschland, 04.-07.10.2010. Tagungsband, 131 (2010).

  • V. Nock, A. Lindauer, U. Jaehde, C. Kloft.
    Leukopenia in cancer patients receiving high-dose chemotherapy and myelosupportive treatment.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG), Braunschweig, Deutschland, 04.-07.10.2010. Tagungsband, 132 (2010).

  • R. Niebecker, K. Kuester, U. Kunz, C. Kloft.
    Comparison of body size descriptors as influential factors in sibrotuzumab population pharmacokinetics.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG), Braunschweig, Deutschland, 04.-07.10.2010. Tagungsband, 77 (2010).

  • A. Schaeftlein, R.A. Keel, J.L. Kuti, C. Kloft.
    Linezolid concentrations in cystic fibrosis patients: Evaluation of competing pharmacokinetic models.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG), Braunschweig, Deutschland, 04.-07.10.2010. Tagungsband, 132 (2010).

  • C. Kirbs, A. Simm, J. Wohlrab, C. Kloft.
    A valid method for quantification of cytokines from microdialysate contributing to biomarker profiling.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG), Braunschweig, Deutschland, 04.-07.10.2010. Tagungsband, 136 (2010).

  • R.A. Keel, C. Kloft, A. Schaeftlein, J. Pope, R. Knauft, D. Nicolau, J.L. Kuti.
    Population pharmacokinetics (PK) of intravenous (IV) and oral (PO) linezolid (LZD) in adults with cystic fibrosis (CF).
    Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston,
    United States of America, 12.-15.09.2010. Abstract book A1-009 (2010).

  • C. Kloft.
    Pharmacometrics and systems biology: Do they fit?
    3rd International Worrkshop on Systems Biology, Maynooth, Irland, 15.-18.08.2010. Abstract book 18 (2010).

  • M. Frank, A. Kunz, G. Harms, J.S. Van der Walt, C. Kloft.
    Population pharmacokinetic model building for mothers and newborns using additional information from a different nevirapine dataset.
    19th Population Approach Group Europe (PAGE), Berlin, Germany, 08.-11.06.2010. [www.page-meeting.org/?abstract=1814], (2010).

  • V. Nock, A. Lindauer, U. Jaehde, C. Kloft.
    Leukopenia following high-dose chemotherapy with autologuos stem cell retransfusion in patients with testicular cell cancer.
    19th Population Approach Group Europe (PAGE), Berlin, Germany, 08.-11.06.2010.
    [www.page-meeting.org/?abstract=1826], (2010).

  • R. Niebecker, K. Kuester, U. Kunz, C. Kloft.
    Impact of different body size descriptors on the population pharmacokinetics of a monoclonal antibody.
    19th Population Approach Group Europe (PAGE), Berlin, Germany, 08.-11.06.2010.
    [www.page-meeting.org/?abstract=1943], (2010).

  • M. Frank, A. Kunz, G. Harms, C. Kloft.
    Nevirapine - Population pharmacokinetic model building and evaluation for mothers and newborns.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2009, Jena, 29.-01.10.09. Abstractband, K16 (2009).

  • M. Scholz, C. Kloft.
    Systematic Investigation of the Midinterval Method in Microdialysis
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2009, Jena, 29.-01.10.09. Abstractband, E05 (2009).

  • F. Simmel, M. Zeitlinger, Z. Erdogan, E. Lackner, C. Kloft.
    Feasibility of Long-term Microdialysis with Moderately Lipophilic Voriconazole in Humans.
    49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, USA, 12.-15.09.2009. Abstract CD-ROM, A1-589 (2009).

  • M. Frank, A. Kunz, G. Harms, C. Kloft.
    Population pharmacokinetic model development and evaluation after nevirapine administration to mothers and newborns.
    18th Population Approach Group Europe (PAGE), St. Petersburg, Russia, 23.-26.06.2009. [www.page-meeting.org/?abstract=1484], (2009).

  • M. Scholz, C. Kloft.
    Optimal Design for the improvement of sampling schedules of microdialysis studies. 18th Population Approach Group Europe (PAGE), St. Petersburg, Russia, 23.-26.06.2009. [www.page-meeting.org/?abstract=1485], (2009).

  • J. Gloede, C. Scheerans, C. Kloft.
    PK/PD-Modelling of Vancomycin Resistant Enterococcus Faecium Growing Under Constant Linezolid Exposure.
    Bad Honnef-Symposium 2009, Königswinter, 06.-07.04.2009. Chemother. J., 18: 70 (2009).

  • K. Kuester, A. Kovar, C. Lüpfert, B. Brockhaus, C. Kloft.
    The pharmacokinetics of matuzumab - a novel monoclonal antibody.
    28th Annual German Cancer Congress, Berlin, Germany, 20.-23.02.2008. Abstractband 136 (2008).

  • S. Balke, R. Frontini, C. Kloft.
    Klinischer Vergleich zweier Pflasterentfernungsmittel bei kritisch kranken Patienten.
    23. Wissenschaftlicher ADKA-Kongress, Lübeck, 29.05.-01.06.2008.
    Krankenhauspharmazie, 29: 238 (2008).

  • K. Kuester, A. Kovar, C. Lüpfert, B. Brockhaus, C. Kloft.
    Matuzumab - evaluation of the population pharmacokinetic model and analyses of the covariate impact on the pharmacokinetic profile.
    17th Population Approach Group Europe (PAGE), Marseille, France, 18.-20.06.2008. [www.page-meeting.org/?abstract=1244] (2008).

  • M. Frank, A. Kunz, G. Harms, C. Kloft.
    Nevirapine - Population pharmacokinetic model building and simulation for mothers and newborns.
    17th Population Approach Group Europe (PAGE), Marseille, France, 18.-20.06.2008. [www.page-meeting.org/?abstract=1249] (2008).

  • A. Lindauer, C. Eickhoff, C. Kloft, U. Jaehde.
    Population pharmacokinetics of high-dose carboplatin.
    17th Population Approach Group Europe (PAGE), Marseille, France, 18.-20.06.2008. [www.page-meeting.org/?abstract= 1303] (2008).

  • C. Kloft, W. Huisinga, H.G. Schaefer, P. Noertersheuser.
    Launch of the Graduate Research Training (GRT) program 'Pharmacometrics & Computational Disease Modelling' in Germany.
    17th Population Approach Group Europe (PAGE), Marseille, France, 18.-20.06.2008. [www.page-meeting.org/?abstract= 1389] (2008).

  • M. Frank, A. Kunz, G. Harms, C. Kloft.
    Population pharmacokinetics in black newborns for nevirapine to prevent HIV transmission.
    Ehrlich II - 2nd World Conference on Magic Bullets, Nuernberg, 03.-05.10.08. Abstractband online [www.ehrlich-2008.org/scientificprogram.htm], A-96 (2008).

  • J. Gloede, C. Scheerans, C. Kloft.
    Vancomycin resistant Enterococcus faecium under constant linezolid exposure.
    Ehrlich II - 2nd World Conference on Magic Bullets, Nuernberg, 03.-05.10.08. Abstractband online [www.ehrlich-2008.org/scientificprogram.htm], A-106 (2008).

  • F. Simmel, C. Kloft.
    Microdialysis with moderately lipophilic drugs: what is essential to know for voriconazole and its drug product to be applicable in pre-/clinical microdialysis settings?
    Ehrlich II - 2nd World Conference on Magic Bullets, Nuernberg, 03.-05.10.08. Abstractband online [www.ehrlich-2008.org/scientificprogram.htm], A-297 (2008).

  • M. Frank, A. Kunz, G. Harms, C. Kloft.
    Population pharmacokinetics of nevirapine for HIV prevention in newborns.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2008, Bonn, 08.-11.10.08. Abstractband, 274 (2008).

  • J. Gloede, C. Scheerans, C. Kloft.
    PK/PD-modelling of vancomycin resistant Enterococcus growing under constant linezolid exposure.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2008, Bonn, 08.-11.10.08. Abstractband, 275 (2008).

  • C. Kloft, W. Huisinga, H.G. Schaefer, P. Noertersheuser.
    Innovative Graduate Research Training (GRT) program 'Pharmacometrics & Computational Disease Modelling'.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2008, Bonn, 08.-11.10.08. Abstractband, 276 (2008).

  • K. Kuester, A. Kovar, C. Lüpfert, B. Brockhaus, C. Kloft.
    Population pharmacokinetic model for matuzumab - evaluation and simulation.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2008, Bonn, 08.-11.10.08. Abstractband, 277 (2008).

  • U. Hinkel, C. Schuijt, J. Bubeck, L. Petrini, J.F. Erckenbrecht.
    Lifestyle of constipated patients as compared to the general population.
    16th United European Gastroenterology Week (UEGW), Wien, Österreich, 18.-22.10.08, Gut 57 (Suppl. 2): A378 (2008).

  • J. Soukup, F. Simmel, U. Götze, S. Schneider, C. Kloft.
    "Therapeutic Drug Monitoring" während Voriconazol-Sequenztherapie - Eine prospektive Studie bei intensivmedizinischen Patienten.
    9. Deutscher Interdisziplinärer Kongress für Intensivmedizin und Notfallrettung (DIVI) 2008, Hamburg, 03.-06.12.08. Tagungsband, P/10/02 (2008).

  • T. Grobosch, L. Schönberg, D. Lampe, C. Kloft.
    New automated screening system for the determination of basic compounds in urine by on-line extraction-HPLC-DAD.
    XV. Mosbacher Symposium der Gesellschaft für Toxikologische und forensiche Chemie (GTFCh) 2007, Mosbach, 18.-21.04.2007. Abstract book (2007).

  • K. Kuester, A. Kovar, B. Brockhaus, C. Kloft.
    A population pharmacokinetic model for the monoclonal antibody matuzumab.
    Pre-Satellite Meeting of the 3rd Pharmaceutical Sciences World Congress (PSWC), Amsterdam, The Netherlands, 20.-21.04.2007. Tagungsband, 26 (2007).

  • K. Kuester, A. Kovar, B. Brockhaus, C. Kloft.
    A population pharmacokinetic model for the monoclonal antibody matuzumab.
    3rd Pharmaceutical Sciences World Congress (PSWC), Amsterdam, The Netherlands, 22.-25.04.2007. Tagungsband, 48 (2007).

  • K. Kuester, A. Kovar, B. Brockhaus, C. Kloft.
    Matuzumab – A population pharmacokinetic model and its evaluation.
    16th Population Approach Group Europe (PAGE), Copenhagen, Denmark, 13.-15.06.2007. 1090 (2007).

  • F. Simmel, C. Kloft.
    Impact of solubilizing excipients on the feasibility of in vitro and in vivo microdialysis investigations.
    4th International Conference on Clinical Microdialysis (ICCM) 2007, Cambridge, UK, 19.-21.09.2007. Tagungsband, 125 (2007).

  • K. Kuester, A. Kovar, C. Lüpfert, B. Brockhaus, C. Kloft.
    Population pharmacokinetics of matuzumab – A monoclonal antibody with complex elimination.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2007, Erlangen, 10.-13.10.2007. Tagungsband, 50 (2007).

  • O. Schwalbe, C. Kloft.
    Strategies for Optimising Compliance in Psychiatric Patients.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2007, Erlangen, 10.-13.10.2007. Tagungsband, 160 (2007).

  • F. Simmel, D.M. Saunte, L.B. Stolle, M.C. Arendrup, C. Kloft.
    Feasibility to determine in vivo voriconazole exposure in healthy versus inflamed skin by microdialysis.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2007, Erlangen, 10.-13.10.2007. Tagungsband, 138 (2007).

  • J. Glöde, C. Scheerans, C. Kloft.
    In vitro investigations to quantify the effects of antibiotics using linezolid as model drug.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2007, Erlangen, 10.-13.10.2007. Tagungsband, 138 (2007).

  • O. Schwalbe, I. Freiberg, C. Kloft.
    Adherence of Alzheimer Patients to Antidementia Drugs.
    Annual European Congress of the International Scoiety for Pharmacoeconomics and Outcomes Research (ISPOR) 2007, Dublin, 20.-23.10.2007. Value Health, 10: A303 (2007).

  • T. Lehr, A. Staab, C. Tillmann, D. Trommeshauser, A. Raschig, H.G. Schaefer, C. Kloft.
    Population pharmacokinetics of NS2330 and its major metabolite in Alzheimer’s disease patients.
    15th Population Approach Group Europe (PAGE), Brugge, Belgium, 14.-16.06.2006. 986 (2006).

  • T. Lehr, A. Staab, C. Tillmann, D. Trommeshauser, A. Raschig, H.G. Schaefer, C. Kloft.
    Efficacy modelling of NS2330 in mild Alzheimer’s disease patients.
    15th Population Approach Group Europe (PAGE), Brugge, Belgium, 14.-16.06.2006. 985 (2006).

  • D. Zeumer, A. Staab, T. Lehr, C. Tillmann, K.H. Liesenfeld, H.G. Schaefer.
    PROPHET - A convenient and efficient environment for the use of NONMEM in a global pharmaceutical company.
    15th Population Approach Group Europe (PAGE), Brugge, Belgium, 14.-16.06.2006. 990 (2006).

  • N. Plock, C. Buerger, K. Kuester, C. Joukhadar, S. Kljucar, C. Kloft.
    A Population Pharmacokinetic Model for the Simultaneous Description of Linezolid Tissue and Plasma Disposition in Healthy Volunteers and Septic Patients.
    15th Population Approach Group Europe (PAGE), Brügge, Belgien, 14.-16.06.2006. 886 (2006).

  • K. Kuester, A. Kovar, B. Brockhaus, C. Kloft.
    Population pharmacokinetic analysis for matuzumab (EMD 72000) – a humanised EGFR-targeted monoclonal antibody.
    15th Population Approach Group Europe (PAGE), Brugge, Belgium, 14.-16.06.2006. 971 (2006).

  • A. Hartmann, J. Brüggmann, B. Barthel, U. Häckert, C. Kloft.
    Überprüfung der Dosierung bei stationären Patienten mit Niereninsuffizienz.
    Krankenhauspharmazie, 27: 222 (2006).

  • L. Schönberg, T. Grobosch, D. Lampe, C. Kloft.
    Development of a fully automated screening system for the determination of basic compounds in urine by on-line extraction – high performance liquid chromatography with photodiode-array detection.
    44th International meeting of the International Association of Forensic Toxicologists (TIAFT), Ljubljana, Slowenien, 26.08-01.09.2006. Tagungsband 44 (2006).

  • C. Kloft.
    Application of modelling and simulation in oncology.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2006, Marburg, 04.-07.10.2006. Tagungsband, 52 (2006).

  • L. Schönberg, T. Grobosch, D. Lampe, B. Erxleben, C. Kloft.
    Development of an automated screening system for the determination of substances in urine.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2006, Marburg, 04.-07.10.2006. Tagungsband, 75 (2006).

  • K. Kuester, A. Kovar, B. Brockhaus, C. Kloft.
    Matuzumab – a population pharmacokinetic analysis.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2006, Marburg, 04.-07.10.2006. Tagungsband, 95 (2006).

  • O. Schwalbe, C. Kloft.
    Adherence to antidementia drugs determined by electronic monitoring.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2006, Marburg, 04.-07.10.2006. Tagungsband, 97 (2006).

  • N. Plock, C. Joukhadar, S. Kljucar, C. Kloft.
    Population Pharmacokinetics of Linezolid in Tissue and Plasma of Healthy Subjects and Septic Patients – Managing Nonlinearity.
    46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, USA, 27.-30.09.2006. Tagungsband, 30 (2006).

  • L.B. Stolle, N. Plock, C. Joukhadar, M. Mueller, M. Arpi, C. Buerger, P. Riegels Nielsen, C. Kloft.
    Pharmacokinetics of linezolid in bone tissue investigated by in situ microdialysis.
    European Congress of Clinical Microbiology and Infectious Diseases 2005, Kopenhagen, 02.-05.04.2005. Clin. Microbiol. Infect., 11: 30 (2005).

  • C. Kloft.
    Strategies for optimal dosage regimes of monoclonal antibodies.
    1st PharmSciFair 2005 der European Federation for Pharmaceutical Sciences (EUFEFS), Nizza, 12.-17.06.2005. Abstract-CD (2005).

  • G. Fliss, A. Staab, C. Tillmann, D. Trommeshauser, H.G. Schaefer, C. Kloft.
    Development and evaluation of a population pharmacokinetic model for cilobradine, an If channel blocker.
    14th Annual Meeting der Population Approach Group Europe (PAGE), Pamplona, Spain, 16.-17.06.2005. PAGE, 14: 704 (2005).

  • T. Lehr, C. Tillmann, R. Binder, A. Staab, D. Trommeshauser, H.G. Schaefer, C. Kloft.
    Assessment of the potency of a metabolite relative to the parent compound using a population PK/PD model for the inhibition of a neurotransmitter re-uptake transporter in mice.
    14th Annual Meeting der Population Approach Group Europe (PAGE), Pamplona, Spain, 16.-17.06.2005. PAGE, 14: 730 (2005).

  • T. Lehr, C. Tillmann, R. Krug-Schmid, A. Staab, D. Trommeshauser, H.G. Schaefer, C. Kloft.
    A new CNS active drug and its metabolite: a population pharmacokinetic analysis.
    14th Annual Meeting der Population Approach Group Europe (PAGE), Pamplona, Spain, 16.-17.06.2005. PAGE, 14: 729 (2005).

  • T. Lehr, C. Tillmann, A. Staab, D. Trommeshauser, H.G Schaefer, C. Kloft.
    Evaluation of an enterohepatic circulation model: predicting the influence of cholestyramine on the pharmacokinetics of meloxicam.
    14th Annual Meeting der Population Approach Group Europe (PAGE), Pamplona, Spain, 16.-17.06.2005. PAGE, 14: 766 (2005).

  • C. Tillmann, H.G. Schaefer, T. Lehr, A. Staab.
    Meloxicam for juvenile rheumatoid arthritis patients: Is dosing on a mg/kg body weight basis justified?.
    14th Annual Meeting der Population Approach Group Europe (PAGE), Pamplona, Spain, 16.-17.06.2005. PAGE, 14: 771 (2005).

  • O. Schwalbe, C. Kloft.
    Pharmaceutical Care for Alzheimer’s patients and their caregivers: A pilot study.
    Workshop der Deutschen Pharmazeutischen Gesellschaft (DPhG) – Fachgruppe Klinische Pharmazie 2005, Düsseldorf, 02.-03.09.2005.

  • K. Kuester, J. Tillner, B. Brockhaus, A. Kovar, C. Kloft.
    Population pharmacokinetic approach for matuzumab – a humanised monoclonal antibody.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2005, Mainz, 05.-08.10.2005. Tagungsband, 94 (2005).

  • T. Lehr, C. Tillmann, A. Staab, D. Trommeshauser, H.G. Schaefer, C. Kloft.
    Mechanistic PK modelling to overcome limitations in drug-drug interaction studies of long half-life drugs.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2005, Mainz, 05.-08.10.2005. Tagungsband, 95 (2005).

  • N. Plock, C. Buerger, C. Joukhadar, M. Mueller, S. Kljucar, C. Kloft.
    Are we all the same? - population pharmacokinetics of linezolid in tissue and plasma.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2005, Mainz, 05.-08.10.2005. Tagungsband, 74 (2005).

  • C. Scheerans, J. Wagner, U.B. Göbel, C. Kloft.
    Development of a pharmacokinetic/pharmacodynamic approach for linezolid.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2005, Mainz, 05.-08.10.2005. Tagungsband, 95 (2005).

  • O. Schwalbe, C. Kloft.
    Morbus Alzheimer: Design of a Pharmaceutical Care pilot study.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2005, Mainz, 05.-08.10.2005. Tagungsband, 95 (2005).

  • T. Lehr, C. Tillmann, A. Staab, D. Trommeshauser, H.G. Schaefer, C. Kloft.
    Estimating the maximum impact of CYP3A4 inhibition on the pharmacokinetics of long half-life drugs: a mechanistic modelling approach.
    Annual Meeting der American Assiciation of Pharmaceutical Scientists (AAPS), Nashville, 06.-10.11.2005. AAPS J., 7 (S2): M1306 (2005).

  • N. Plock, C. Bürger, C. Joukhadar, M. Müller, S. Kljucar, C. Kloft.
    Tissue and plasma pharmacokinetics of linezolid - a population approach.
    Annual Meeting der American Assiciation of Pharmaceutical Scientists (AAPS), Nashville, 06.-10.11.2005. AAPS J., 7 (S2): W5329 (2005).

  • L.B. Stolle, N. Plock, C. Joukhadar, M. Arpi, K.J. Emmertsen, C. Buerger, P. Riegels Nielsen, C. Kloft.
    Microdialysis in bone tissue - pharmacokinetics of linezolid.
    Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2005, Washington, 16.-19.12.2005. A29 (2005).

  • G. Fliss, A. Staab, C. Tillmann, D. Trommeshauser, H.G. Schaefer, Kloft C.
    Population pharmacokinetic modelling of cilobradine, an I f channel blocker.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2004, Regensburg, 07.-09.10.2004, Tagungsband, 78 (2004).

  • T. Lehr, R. Krug-Schmid, C. Tillmann, A. Staab, D. Trommeshauser, H.G. Schaefer, C. Kloft.
    Population pharmacokineitc model of a CNS active drug and its metabolite.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2004, Regensburg, 07.-09.10.2004, Tagungsband, 138 (2004).

  • N. Plock, C. Kloft.
    pH-dependency of microdialysis recovery – In vitro microdialysis of vancomycin.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2004, Regensburg, 07.-09.10.2004, Tagungsband, 139 (2004).

  • L. Schönberg, C. Kloft, T. Grobosch, U. Lemm-Ahlers, D. Lampe, B. Erxleben.
    Development of an analytical method for the determination of substances in urine.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2004, Regensburg, 06.-09.10.2004. Tagungsband, 52 (2004).

  • C. Buerger, N. Plock, C. Joukhadar, M. Mueller, C. Kloft.
    Tissue pharmacokinetics of linezolid assessed by microdialysis.
    World Conference on Dosing of Antiinfectives 2004, Nuernberg, 06.-11.09.2004, Tagungsband, 417 (2004).

  • O. Schwalbe, C. Buerger, N. Plock, C. Scheerans, C. Kloft.
    Human Microdialysis: Urea as an Endogenous Reference Compound to Determine Relative Recovery of Drugs.
    World Conference on Dosing of Antiinfectives 2004, Nuernberg, 06.-11.09.2004, Tagungsband, 478 (2004).

  • N. Plock, C. Kloft.
    Special Characteristics of Microdialysis with Vancomycin – pH Dependence of Microdialysis Recovery.
    World Conference on Dosing of Antiinfectives 2004, Nuernberg, 06.-11.09.2004, Tagungsband, 416 (2004).

  • T. Lehr, C. Tillmann, A. Staab, D. Trommeshauser, H.G. Schaefer, C. Kloft.
    Clock time as a control variable for gall bladder emptying in an enterohepatic circulation model.
    Annual of the Population Approach Group in Europe (PAGE), Uppsala, 17.-18.06.2004. 469 (2004).

  • O. Schwalbe, C. Bürger, N. Plock, C. Kloft.
    Harnstoff als endogene Referenzsubstanz zur Bestimmung der In-vivo-Wiederfindung in humanen Mikrodialysat-Proben.
    Deutsche Pharmazeutischen Gesellschaft (DPhG), Landesgruppe Berlin-Brandenburg – Der wissenschaftliche Nachwuchs stellt sich vor, Berlin, 05. Juli 2004, Tagungsband, P24 (2004).

  • L. Schönberg, C. Kloft, T. Grobosch, U. Lemm-Ahlers, D. Lampe, B. Erxleben.
    Entwicklung eines in der toxikologischen Notfall-Diagnostik einsetzbaren Analysenverfahrens.
    Deutsche Pharmazeutischen Gesellschaft (DPhG), Landesgruppe Berlin-Brandenburg – Der wissenschaftliche Nachwuchs stellt sich vor, Berlin, 05.07.2004. Tagungsband, P23 (2004).

  • T. Lehr, C. Tillmann, A. Staab, D. Trommeshauser, H.G. Schaefer, C. Kloft.
    Enterohepatic circulation – Influence on Drug Exposure and Half-Life.
    Deutsche Pharmazeutischen Gesellschaft (DPhG), Landesgruppe Berlin-Brandenburg – Der wissenschaftliche Nachwuchs stellt sich vor, Berlin, 05.07.2004. Tagungsband, V1 (2004).

  • C. Buerger, N. Plock, C. Joukhadar, M. Müller, C. Kloft.
    Pharmakokinetik von Linezolid am Wirkort.
    Deutsche Pharmazeutischen Gesellschaft (DPhG), Landesgruppe Berlin-Brandenburg – Der wissenschaftliche Nachwuchs stellt sich vor, Berlin, 05.07.2004. Tagungsband, V2 (2004).

  • N. Plock, C. Kloft.
    Bestimmung von Vancomycinkonzentrationen im Gewebe von kritisch Kranken: Eine Kombination von Mikrodialyse und HPLC.
    Deutsche Pharmazeutischen Gesellschaft (DPhG), Landesgruppe Berlin-Brandenburg – Der wissenschaftliche Nachwuchs stellt sich vor, Berlin, 05.07.2004. Tagungsband, P20 (2004).

  • S. Sanghani, S. Salek, C. Kloft.
    Ethnographic and participant observation methods of testing the feasibility of undertaking a cross-cultural project in community pharmacy standards. Pharm. World Sci., 26: 33 (2004).

  • P. Dehghanyar, C. Buerger, F. Kovar, C. Kloft, M. Mueller, C. Joukhadar.
    The pharmacokinetics of linezolid for plasma and tissues after single and multiple doses in healthy volunteers.
    Int. J. Clin. Pharmacol. Ther., 7: 412 (2004).

  • O. Schwalbe, C. Buerger, N. Plock, C. Kloft.
    Determination of in vivo recovery in human microdialysis samples: Urea as a reference compound. Int. J. Clin. Pharmacol. Ther., 7: 398 (2004).

  • N. Plock, C. Kloft.
    Tissue concentrations of vancomycin in critically ill patients: Microdialysis combined with a rapid and sensitive HPLC quantification.
    Int. J. Clin. Pharmacol. Ther., 7: 398 (2004).

  • C. Buerger, N. Plock, C. Joukhadar, M. Mueller, C. Kloft.
    Tissue pharmacokinetics of linezolid assessed by microdialysis.
    Int. J. Clin. Pharmacol. Ther., 7: 399 (2004).

  • M. Wonnemann, F. Donath, B. Schug, D. Wolf, G. Stein, S. Schindler, C. Kloft, H. Blume.
    Elimination of propiverine in patients with severe renal impairment – successful ap­­pli­­cation of the 2-stage-approach as recommended by the US-FDA Guidance for Industry.
    Annual Meeting of the Association for Applied Human Pharmacology (AGAH) 2004: Special populations – What makes them so special?, Berlin, 29.02. - 02.03.2004. Abstractband (2004).

  • N. Plock, C. Buerger, C. Kloft.
    Rapid and sensitive HPLC quantification of vancomycin in critically ill patients.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2003, Würzburg, 08.-11.10.2003. Tagungsband 61 (2003).

  • O. Schwalbe, C. Buerger, N. Plock, C. Kloft.
    Urea as a reference compound to deterermine the in vivo recovery in human microdialysis samples.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2003, Würzburg, 08.-11.10.2003. Tagungsband 111 (2003).

  • S. Sanghani, S. Salek, C. Kloft.
    Ethnographic and participant observation methods of testing the feasibility of undertaking a cross-cultural project in community pharmacy standards.
    32nd European Symposium on Clinical Pharmacy, Valencia, 29.10.-01.11.2003.
    Tagungsband, 22 (2003).

  • C. Kloft, U. Graefe, P. Tanswell, A.M. Scott, R. Hofheinz, M. Karlsson.
    Population pharmacokinetics of sibrotuzumab, a novel monoclonal antibody, in cancer patients.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2002, Berlin, 09.-12.10.2002 (Vortrag). Arch. Pharm. Pharm. Med. Chem., 335 (Suppl. 1): 67 (2002).

  • C. Buerger, C. Joukhadar, M. Mueller, C. Kloft.
    Individualization of drug therapy by monitoring drug concentration at the target site of action.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2002, Berlin, 09.-12.10.2002. Arch. Pharm. Pharm. Med. Chem., 335 (Suppl. 1): 37 (2002).

  • G. Fliss, A. Huether, C. Eickhoff, H. Heidecke, C. Kloft.
    First successful step in the development of a determination system to predict the effect time course in tumour therapy.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2002, Berlin, 09.-12.10.2002. Arch. Pharm. Pharm. Med. Chem., 335 (Suppl. 1): 144 (2002).

  • S. Sanghani, C. Buerger, G. Fliß, A. Huether, S. Reif, U. Warnke, C. Kloft.
    Quantitative and qualitative evaluation of the novel Clinical Pharmacy course in Berlin, Germany.
    30 th European Symposium on Clinical Pharmacy, Antwerp, 10.-13.10.2002.
    Pharm. World Sci. 24(1): 39 (2002).

  • C. Eickhoff, H. Heidecke, A. Hüther, C. Kloft.
    Pharmakokinetik/Pharmakodynamik-Testsystem zur Vorhersage des Effektverlaufs in der Tumortherapie. Statusseminar: Tissue engineering und zellbasierte Therapie in der Region Berlin, Berlin Campus Virchow-Klinikum Charité, 29.06.2001. Bio-Med-Net Tagungsband (2001).

  • AGAH working group PK/PD modelling: H. Blode, M. Brett, W. Cawello, A. Frick, R. Gieschke, C. Kloft, A. Kovar, G. Pabst, A. Steinsträsser, H. J. Weigmann, G. Würthwein.
    PK modelling using different software packages.
    3. Jahreskongress für Klinische Pharmakologie, Köln, 15.-17.11.2001. Abstractband S. 31, Nr. 100 (2001).

  • C. Kloft, G. Fliß, C. Schelbert, C. Buerger.
    Pharmakokinetik bei kritisch Kranken: Neue Ansätze für individuelle Dosierungsschemata.
    Gemeinsame Jahrestagung der Deutschen Gesellschaft für Internistische Intensivmedizin und Notfallmedizin und der Österreichischen Gesellschaft für Internistische und Allgemeine Intensivmedizin, Halle, 20.-23.06.2001 (Poster). Intensivmed., 38: 356 (2001).

  • C. Buerger, C. Kloft.
    Development of an integrated pharmacokinetic/pharmacodynamic model for busulfan.
    Joint Meeting der Arbeitsgruppen von CESAR-EWIV, Kiel, 28.-30.06.2001. Int. J. Clin. Pharmacol. Ther., 40: 8 (2002).

  • S. Reif, C. Kloft, A. Jetter, U. Fuhr, H.L. McLeod, W. Schunack, U. Jaehde
    Population pharmacokinetic parameter estimation to assess the impact of dose on etoposide pharmacokinetics.
    10 th Meeting of the Population Approach Group in Europe (PAGE), Basel, 07.-08.06.2001. 224, P53 (2001).

  • S. Reif, M. Nicolson, D. Bissett, C. Kloft, W. Schunack, U. Jaehde, H.L. McLeod.
    Does pre-treatment with grapefruit juice improve etoposide bioavailability?
    3rd European Graduate Student Meeting 2001, Frankfurt/M., 23.-25.02.2001. Arch. Pharm. Pharm. Med. Chem., 334 (Suppl. 1): 8 (2001).

  • C. Kloft, G. Fliß, S. Reif, C. Schelbert, U. Warnke.
    Innovative teaching and education programme in Clinical Pharmacy at the Freie Universitaet Berlin.
    29 th European Symposium on Clinical Pharmacy, Basel, 11.-14.10.2000 (Vortrag und Poster). Pharm. World Sci., 22 (5/6): 180-181 (2000).

  • S. Reif, M.C. Nicolson, D. Bissett, C. Kloft, W. Schunack, U. Jaehde, H.L. McLeod.
    Influence of grapefruit juice on etoposide bioavailability.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2000, Münster, 04.-07.10.2000 (Poster). Arch. Pharm. Pharm. Med. Chem., 333 (Suppl. 2): 27 (2000).

  • C. Kloft, G. Fliß, S. Reif, B. Schwabe, C. Schelbert, U. Warnke.
    Kursus „Klinische Pharmazie, Pharmazeutische Betreuung, Pharmakotherapie“ an der Freien Universität Berlin.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2000, Münster, 04.-07.10.2000.
    Arch. Pharm. Pharm. Med. Chem., 333 (Suppl. 2): 76 (2000).

  • S. Reif, G. Fleischhack, H. Deisel, S. Hettmer, C. Hasan, U. Bode, C. Kloft, W. Schunack, U. Jaehde.
    Pharmacokinetics of etoposide following intraventricular administration.
    14. Jahrestreffen der APOH, Bonn, 26.-27.05.2000. Int. J. Clin. Pharmacol. Ther., 39: 92 (2001).

  • S. Reif, M.C. Nicolson, D. Bissett, C. Kloft, W. Schunack, U. Jaehde, H.L. McLeod.
    Altered bioavailability of etoposide after pre-treatment with grapefruit juice.
    14. Jahrestreffen der APOH, Bonn, 26.-27.05.2000. Int. J. Clin. Pharmacol. Ther., 39: 90-91 (2001).

  • C. Kloft, G. Fliß, B. Schwabe, C. Schelbert, W. Siegert.
    New approaches for dosing regimens in patients with pharmacokinetic/pharmaco­dynamic modeling.
    Jahrestagung der Deutschen Pharmazeutischen Gesellschaft (DPhG) 2000, Münster, 04.-07.10.2000 (Poster). Arch. Pharm. Pharm. Med. Chem., 333 (Suppl. 2): 37 (2000).

  • C. Kloft, G. Fliß, S. Reif, B. Schwabe, U. Warnke, W. Schunack.
    Kursus „Klinische Pharmazie, Pharmazeutische Betreuung, Pharmakotherapie“ an der Freien Universität Berlin.
    28. Wissenschaftlicher Kongress, ADKA, Köln, 04.-07.05.2000 (Poster). Krankenhauspharmazie, 21: 250 (2000).

  • U. Warnke, C. Kloft, W. Schunack, U. Jaehde.
    Capillary Electrophoretic Analysis of Platinum-DNA Adducts: Optimization of Separation and First Kinetic Investigations.
    2 nd European Graduate Student Meeting 2000, Frankfurt/M., 03.-05.03.2000. Arch. Pharm. Pharm. Med. Chem., 333 (Suppl. 1): 20 (2000).

  • S. Reif, J. Grimm, D. Kingreen, W. Siegert, C. Kloft, W. Schunack, U. Jaehde.
    Randomised comparison of etoposide pharmacokinetics after high-dose etoposide and etoposide phosphate.
    28 th European Symposium on Clinical Pharmacy, Berlin, 14.-16.10.1999. Abstractband, P161 (1999).

  • U. Warnke, J. Gysler, A.J.P. Hofte, U.R. Tjaden, J. van der Greef, C. Kloft, W. Schunack, U. Jaehde.
    Separation and identification of platinum-DNA adducts by application of capillary electrophoresis coupled to mass spectrometry.
    DPhG-Jahrestagung Frankfurt, 06.-09.10.1999. Arch. Pharm. Pharm. Med. Chem., 332 (Suppl. 2): 51 (1999).

  • S. Reif, G. Fleischhack, U. Bode, C. Kloft, W. Schunack, U. Jaehde.
    Pharmacokinetics of intraventricular etoposide in patients with metastatic medulloblastoma.
    DPhG-Jahrestagung Frankfurt, Vorsymposium III, 06.-07.10.1999. Arch. Pharm. Pharm. Med. Chem., 332 (Suppl. 2): 57 (1999).

  • G. Hempel, C. Eickhoff, C. Kloft, U. Jaehde.
    Comparison of three methods to analyse the population pharmacokinetics of high-dose carboplatin in patients with testicular carcinoma.
    8. PAGE-Meeting, Saintes, Frankreich, 17.-18.06.1999. 154 (1999).

  • C. Eickhoff, C. Kloft, W. Siegert, U. Bode, N. Frickhofen, M. Koenigsmann, W. Schunack, U. Jaehde.
    Effect of infusion time on the pharmacokinetics and cerebrospinal fluid (CSF) distribution of high-dose carboplatin.
    Winter Meeting of the EORTC-PAMM group, Amsterdam, 21.-23.01.1999. Abstractband (1999).

  • C. Eickhoff, C. Kloft, W. Siegert, U. Bode, N. Frickhofen, W. Schunack, U. Jaehde
    Continuous infusion of high-dose carboplatin - pharmacokinetics and cerebrospinal fluid distribution.
    Gemeinsames Symposium der Phase I und II Studiengruppe, der APOH und AWO der AIO in der Deutschen Krebsgesellschaft, Freiburg, 02.-04.07.1998. Tumordiagn. Ther., 20: 181 (1999).

  • U. Jaehde, C. Kloft, H. Schöning, W. Siegert.
    Development of an individualized dosing strategy for high-dose carboplatin using the target AUC approach.
    Gemeinsames Symposium der Phase I und II Studiengruppe, der APOH und AWO der Arbeitsgemeinschaft Internistische Onkologie in der Deutschen Krebsgesellschaft, Freiburg, 02.-04.07.1998. Tumordiagn. Ther., 20: 180 (1999).

  • C. Kloft, H. Schöning, W. Siegert, U. Jaehde.
    Dosage optimization based on pharmacokinetic/pharmacodynamic relationships using carboplatin as an example.
    DPhG-Jahrestagung Tübingen, Vorsymposium I, 05.-06.11.1998 (Vortrag). Arch. Pharm. Pharm. Med. Chem., 331 (Suppl. 2): KP32 (1998).

  • C. Eickhoff, C. Kloft, W. Siegert, G. Fleischhack, U. Bode, N. Frickhofen, M. Koenigsmann, W. Schunack, U. Jaehde.
    Pharmacokinetics and cerebrospinal Fluid (CSF) distribution of continuously infused high-dose carboplatin.
    DPhG-Jahrestagung Tübingen, Vorsymposium I, 05.-06.11.1998. Arch. Pharm. Pharm. Med. Chem., 331 (Suppl. 2): KP33 (1998).

  • C. Eickhoff, C. Kloft, W. Schunack, U. Jaehde
    Einfluß der Infusionsdauer auf die Pharmakokinetik von Carboplatin. Tagung der Landesgruppe Berlin-Brandenburg der DPhG, Berlin, 29.06.1998. Abstractband (1998).

  • U. Jaehde, C. Kloft, H. Schöning, W. Siegert.
    Individualized dosing of carboplatin in high-dose chemotherapy: a strategy to minimize toxicity?
    23. Krebskongress, Berlin, 08.-12.06.1998. J. Cancer Res. Clin. Oncol., 124 (Suppl.): R128 (1998).

  • C. Kloft, H. Schöning, W. Siegert, U. Jaehde.
    AUC-guided dosing of carboplatin: an option for high-dose chemotherapy?
    4 th Symposium on High-Dose Chemotherapy and Stem Cell Transplantation in Solid Tumors, Berlin, 17.-18.04.1998 (Vortrag). Abstractband (1998).

  • C. Kloft, C. Eickhoff, U. Jaehde, K. Schulze-Forster, W. Siegert, H.R. Maurer, W. Schunack.
    Development and application of a method to determine platinum-DNA adduct in white blood cells.
    Gemeinsamer Jahreskongress der Schweizerischen Gesellschaft Pharmazeutischer Wissenschaften (SGPhW) und der Deutschen Pharmazeutischen Gesellschaft (DPhG), Zürich, 02.-05.10.1997 (Poster). Abstractband, P42 (1997).

  • U. Jaehde, C. Kloft, W. Saleming, H. Schöning, W. Siegert.
    Relationships between systemic exposure and treatment-associated toxicity of high-dose carboplatin and etoposide.
    Gemeinsamer Jahreskongress der Schweizerischen Gesellschaft Pharmazeutischer Wissenschaften (SGPhW) und der Deutschen Pharmazeutischen Gesellschaft (DPhG), Zürich, 02.-05.10.1997 (Poster). Abstractband, P41 (1997).

  • C. Eickhoff, C. Kloft, U. Jaehde.
    Measurements of platinum-DNA adduct levels in patients – methodology and perspectives for platinum-based chemotherapy.
    5. Norddeutscher Zytostatikaworkshop, Hamburg, 06.-08.02.1997. Abstractband (1997).

  • C. Kloft, U. Jaehde, K. Schulze-Forster, H. Schöning, C. Eickhoff, W. Siegert, H.R. Maurer, W. Schunack.
    Pharmacokinetics and DNA adduct formation of high-dose carboplatin.
    Winter Meeting of the EORTC PAMM Group, Münster, 15.-18.01.1997 (Vortrag). Abstractband: Drug Monitoring and Targeting I and II (1997).

  • U. Jaehde, S. Stremetzne, C. Kloft, J. Steuer, J. Beyer, W. Siegert.
    Pharmacokinetics of carboplatin, etoposide and its cytotoxic catechol metabolite in patients with germ cell cancer receiving high-dose chemotherapy.
    3 rd Symposium on High-Dose Chemotherapy and Stem Cell Transplantation in Solid Tumors, Berlin, 27.-28.04.1996. Abstractband (1996).

  • C. Kloft, U. Jaehde, J. Beyer, J. Steuer, W. Siegert, W. Schunack.
    Clinical pharmacokinetics and time-dependent binding of high-dose carboplatin to plasma proteins and DNA.
    24 th European Symposium on Clinical Pharmacy, Prag, 10.-13.10.1995 (Vortrag). Pharm. World Sci., 17 (Suppl. J): J9 (1995).

  • U. Jaehde, S. Stremetzne, C. Kloft, J. Beyer, J. Steuer, W. Siegert.
    The role of pharmacokinetics in high-dose chemotherapy containing carboplatin and etoposide.
    4 th International Symposium on Oncology Pharmacy Practice, Hamburg, 03.-06.05.1995. J. Oncol. Pharm. Practice, 1: 15 (1995).

  • U. Jaehde, S. Stremetzne, C. Kloft, J. Beyer, J. Steuer, W. Siegert, W. Schunack.
    Pharmacokinetics of carboplatin and etoposide during a high-dose treatment.
    9 th Annual Meeting of American Association of Pharmaceutical Scientists, San Diego, 06.-10.11.1994. Pharm. Res., 11 (Suppl.): S-99 (1994).